Download Cancer Research Institute 2013 Annual Report

2013 ANNUAL REPORT
CANCER RESEARCH INSTITUTE | 1
TABLE OF CONTENTS
3
MISSION STATEMENT
26
HONOR ROLL OF DONORS
4
STATEMENT FROM THE CO-CHAIRMEN
36
HELEN COLEY NAUTS SOCIETY
5
STATEMENT FROM THE SCIENTIFIC
ADVISORY COUNCIL DIRECTOR
38
CENTENNIAL CIRCLE
MESSAGE FROM THE CEO AND DIRECTOR
OF SCIENTIFIC AFFAIRS
39
BOARD OF TRUSTEES
40
SCIENTIFIC ADVISORY COUNCIL
42
OTHER SCIENTIFIC AND LAY LEADERSHIP
45
GIVING TO THE CANCER RESEARCH INSTITUTE
6
7
MISSION AND MAJOR PROGRAMS
12
NOTABLE RESEARCH ACHIEVEMENTS
15
GRANTS & AWARDS
23
FINANCIAL SUMMARY
Cover (clockwise from top left):
Jedd D. Wolchok, M.D., Ph.D. • Juan R. Cubillos-Ruiz, Ph.D. • Lisa C. Osborne, Ph.D. • Kunle Odunsi, M.D., Ph.D. • Carl H. June, M.D. •
Pamela J. Bjorkman, Ph.D. • Joseph C. Sun, Ph.D. • Cathy A. Ferrara, R.N., Nasser K. Altorki, M.D., and Sacha Gnjatic, Ph.D. • Ian H. Frazer, M.D., FRCPA
OUR MISSION:
SAVING MORE
LIVES WITH
IMMUNE-BASED
CANCER TREATMENTS
The Cancer Research Institute is dedicated to extending cancer patients’
lives and reducing cancer-related deaths by fueling the development
of a new class of smarter, more effective treatments that mobilize our
body’s natural immune defenses against all types of cancer.
To accomplish this goal, CRI supports the most critical research, invests
in the early development of promising new treatments, and unites
the efforts of the field’s leaders worldwide. Through this work, CRI
is transforming the paradigm of cancer therapy, enabling patients
to live longer, healthier lives free from the fear of cancer.
CANCER RESEARCH INSTITUTE | 1
STATEMENT FROM THE CO-CHAIRMEN
Our mission has never been more immediately vital: CRI’s 60 years of supporting
research has led to new, life-saving treatments that harness the immune system’s
power to fight cancer.
The recent flurry of news reports of patients helped by cancer immunotherapy
demonstrates the rapid progress we are making. Previously incurable patients are
seeing their cancers stabilize or regress, and many of them remain cancer free years
after treatment.
As co-chairmen of the organization that has stood behind cancer immunotherapy
from the beginning, we take pride in knowing that the Cancer Research Institute is
playing a critical role in offering new hope and better options to cancer patients. By
funding the scientists and clinicians who discover and bring these new treatments to
people who need them, CRI is making a real and important impact today.
With these advances come new opportunities for CRI to lead the way in cancer
immunotherapy discovery and development. Our strategies to kick-start clinical,
translational, and laboratory research have produced significant accomplishments.
In the past year, we have given our scientists unprecedented access to more than 25
promising immunotherapies, provided more than $14.6 million in catalytic program
funding, and launched a new cancer immunotherapy awareness campaign that will
help to raise public awareness of CRI’s position as the leader in immunotherapy.
And, once again, we did this while keeping overhead costs under 15 percent, earning
us top ratings from charity watchdog organizations.
None of this would be possible without the generous support of our donors, for which
we are deeply grateful. We are pleased to announce that gifts from individuals,
corporations, and foundations increased 18 percent over the past year—a testament
to the strengthening confidence in CRI’s ability to find cures for cancer. A complete
financial accounting can be found at the back of this report.
Our Board of Trustees continues to provide oversight as well as business acumen
to ensure the stability and well-being of CRI’s operations. Over the past year, we welcomed new members Robert C. Galvin and
James A. Stern, whose extensive financial management experience and commitment to conquering cancer will benefit CRI.
Brian Brille, who has served as a CRI trustee since 2006, has stepped down from the board. We thank him for his service and
generosity over the years. And longtime trustee and 2006 Grace Award winner Julian H. Robertson Jr. has become a trustee
emeritus. His support and wisdom continue to sustain CRI’s mission in meaningful ways.
Tragically, cancer claimed the life of past CRI president Patrick J. McGrath in early 2013. Pat, who received CRI’s first ever
Helen Coley Nauts Service Award in 2007, was a devoted member of the board and his presence at the table will be sorely
missed. We offer our sincerest condolences to his wife, Patricia, and family.
With each loss of life to cancer, we grow more resolved in our conviction that we can and will end this disease as we know it.
Our work to advance immunotherapy is already transforming cancer treatment, and this is just the beginning. We are confident
that we will, in the very near term, realize the mission CRI’s founders set out to accomplish 60 years ago. Thank you for being
a part of this amazing journey.
John B. Fitzgibbons
Co-Chairman
Paul C. Shiverick
Co-Chairman
STATEMENT FROM THE SCIENTIFIC ADVISORY COUNCIL DIRECTOR
The era of immunotherapy for cancer has begun. Spurred by clinical successes
with FDA-approved vaccines to prevent cervical cancer (2006) and treat prostate
cancer (2010), and with the approval of the first immune checkpoint blockade
therapy (2011) to treat patients with advanced melanoma, the field of cancer
immunology is charged with a new sense of excitement and urgency.
Expectations for immunotherapy’s potential to revolutionize cancer treatment rose
significantly this past year with the announcement in June of results from a clinical
trial testing two immune checkpoint blockades given together in combination to patients
with metastatic melanoma. More than half of patients treated with the optimal dose
experienced remissions of more than 80 percent tumor burden—a jaw-dropping
result. Even more tantalizing, patients who did respond are experiencing long-term
remissions, thanks to the immune system’s capacity for memory.
Immunotherapy’s ability to confer durable protection offers significant advantages
over traditional treatments, whose cancer-fighting effects are typically limited to the
time of treatment. The possibility of achieving long-term remissions—or cures, for
all intents and purposes—offers inspiration to the many scientists working in this
field, who firmly believe that their work will one day help to improve the lives of
cancer patients.
Therapeutic breakthroughs like these do not happen overnight. They rely on years of basic research being conducted in
laboratories all over the world, by scientists asking fundamental questions about how the immune system works. There are
no short-cuts to therapeutic advances. And many times, one doesn’t always know if a basic discovery in the lab will lead to
a promising clinical approach. That’s why CRI remains dedicated to funding laboratory scientists exploring the frontiers of
knowledge. Over and over again, this strategy has paid off, and we have every reason to believe it will continue.
Simultaneously, CRI is placing intense focus on optimizing immunotherapeutic strategies to increase the overall survival rate of
cancer patients. Finding the right combinations of drugs, in the right doses, administered in the right order, and given to the right
populations of cancer patients all remain important next steps in this goal. CRI’s Clinical Accelerator is well positioned to make
substantial progress on this front, helping to bring clinical benefit to patients sooner.
Though many questions remain, the basic discoveries of previous generations of scientists have made today’s treatment
breakthroughs possible. CRI’s ongoing commitment to both basic and clinical research is creating a path to the cancer
immunotherapies of tomorrow.
On behalf of the Scientific Advisory Council, I express the scientific community’s deep appreciation for the generous support
of CRI’s donors who make this work possible. Together, we will conquer cancer in our lifetimes.
James P. Allison, Ph.D.
Director, Scientific Advisory Council
CANCER RESEARCH INSTITUTE | 3
MESSAGE FROM THE CEO AND DIRECTOR OF SCIENTIFIC AFFAIRS
Dear Friends,
Immunotherapy isn’t yet a household word. But it soon will be.
As the many promising new immune-based drugs in clinical trials today make their
way into the mainstream of cancer treatment, more cancer patients and their loved
ones will come to understand just how radically immunotherapy is changing how we
experience and treat this disease.
As CRI celebrates its 60th anniversary this year, we look back over the decades and
find the many ways that funding from our organization has made a key difference.
This difference has meant more lives saved, sooner, and it is something in which
our entire community of supporters and scientists should take pride.
We’ve come very far since 1953, but there is much more work to be done in order
to fully realize immunotherapy’s potential. Immunotherapy is currently approved
for treating only a handful of cancers. Our work now is to help accelerate the
development of immunotherapies for many more, if not all, cancer types.
Thanks to generous support from our donors, we are able to continue leading the
field through our nimble and responsive research and public information programs.
These initiatives allow CRI to be a resource for academic and industry scientists as
well as cancer patients seeking information about cancer immunotherapy and clinical
trials.
Being a leader means we choose to solve the critical problems that others can’t or
won’t, and find ways to get others to work together with us in this effort. Our strong
partnerships with other nonprofits like Ludwig Cancer Research, the American
Association for Cancer Research, and Stand Up To Cancer, and with for-profit
companies like AstraZeneca/MedImmune, Bristol-Myers Squibb, and Immune Design
allow us to leverage and share our resources to increase efficiencies while bringing
life-saving immunotherapies to more patients sooner.
Through leadership and collaboration, we break through barriers to progress. Our
Clinical Accelerator program, for example, allows us to combine complementary
agents owned by different companies while enabling top academic researchers to
study the results. This model of research partnership produces highly reliable data
derived from state-of-the-art clinical trials, and answers the most critical scientific
questions while immediately benefiting cancer patients.
On behalf of the staff of the Cancer Research Institute, I thank you for your support
of our work and look forward to sharing with you news of even greater immunotherapy
successes over the years to come.
Sincerely,
Jill O’Donnell-Tormey, Ph.D.
Chief Executive Officer & Director of Scientific Affairs
MISSION AND MAJOR PROGRAMS
The Cancer Research Institute (CRI), established in 1953, is
the world’s only nonprofit organization dedicated exclusively
to transforming cancer patient care by advancing scientific
efforts to develop new and effective immune system-based
strategies to diagnose, treat, and cure cancer.
Guided by a world-renowned Scientific Advisory Council that includes three Nobel
laureates and twenty-six members of the National Academy of Sciences, CRI has
invested $263 million in support of research conducted by immunologists and
tumor immunologists at the world’s leading medical centers and universities, and
has contributed to many of the key scientific advances that demonstrate the
potential for immunotherapy to change the face of cancer treatment.
To accelerate the pace of progress in the field, CRI convenes and coordinates global
collaborations among academics, industry scientists and decision makers, regulatory
representatives, and health research associations focused on discovery, development,
and refinement of new cancer immunotherapies.
A founding visionary and scientific leader in tumor immunology, CRI is helping to
shape the emerging field of cancer immunotherapy, and is ushering in a new era of
medical progress to bring more treatment options to cancer patients sooner.
The Cancer Research Institute has one of the lowest overhead expense ratios among
nonprofit organizations, with more than 86 percent of its resources going directly to
the support of its science, medical, and research programs.
CRI meets or exceeds all 20 standards of the Better Business Bureau Wise Giving
Alliance, the most comprehensive U.S. charity evaluation service, and has earned
the GuideStar Exchange Seal, indicating our commitment to the transparency of
our organizational information to donors, funders, those we serve, the public, and
regulators. CRI has also received an ‘A’ grade for fiscal disclosure and efficiency
from the American Institute of Philanthropy, as well as top accolades from other
charity watchdog organizations, including the highest rating, four out of four
stars, from Charity Navigator.
For more information, visit us on the web at
www.cancerresearch.org.
Two years ago, when the parents of
Emily Whitehead, now aged 8, realized
that chemotherapy could no longer help
their daughter fight her leukemia, they
looked to the leading edge of scientific
research in hope of finding something,
anything that would cure their ailing
child. Kari and Tom Whitehead enrolled
their daughter in a clinical trial of a new
immunotherapy that had never before
been tried in children.
The risks were high, but then so were
the stakes. Emily’s doctors at the Children’s Hospital of Philadelphia extracted
her immune cells, exposed them to
a modified and safe form of the HIV
virus that genetically re-engineered her
immune cells to attack her leukemia,
and then gave them back to Emily. The
technique, developed by CRI scientist
Carl H. June, M.D., put Emily’s immune
cells through a kind of medical “boot
camp,” training them to become better
cancer killers.
Almost immediately, she began to
show signs of an immune response.
Miraculously, within weeks, she was
completely free of leukemia. Now, more
than a year since her treatment, Emily
remains cancer free and enjoys the
normal, everyday life of a young child
growing up in a small Pennsylvania
town.
Learn more about Emily’s story here:
www.cancerresearch.org/emily-whitehead
CANCER RESEARCH INSTITUTE | 5
MISSION AND MAJOR PROGRAMS (continued)
RESEARCH PROGRAMS
STUDENT TRAINING AND RESEARCH IN TUMOR IMMUNOLOGY (START)
The Student Training and Research in Tumor Immunology (STaRT) program seeks to attract bright young minds to rewarding
careers as cancer immunologists. STaRT grants provide up to $60,000 of support over two years for graduate students conducting
thesis research in the area of tumor immunology. Students selected for the program can receive early exposure during their formative
studies to exciting, emerging areas of investigation within the field of cancer immunology. In addition, student participation in
annual Cancer Research Institute symposia introduces them into the tight-knit community of leading tumor immunologists —
helping to establish a relationship between these up-and-coming research leaders and the Institute. In fiscal year 2013, CRI
awarded four new STaRT grants totaling $240,000.
PREDOCTORAL EMPHASIS PATHWAYS IN TUMOR IMMUNOLOGY
Initiated in 1998, the Predoctoral Emphasis Pathways program provides funding to universities to establish training curricula
designed to capture the interest of talented researchers at the earliest stage. Grants support doctoral students planning to pursue
a career in cancer immunology. Through meetings, journal clubs, lectures, and coursework, students receive early exposure during
their formative studies to emerging areas in the field of tumor immunology. CRI provided ongoing grant support to nine institutions in
the U.S., Australia, and Russia.
IRVINGTON POSTDOCTORAL FELLOWSHIP PROGRAM
The CRI Irvington Postdoctoral Fellowship Program, established in 1971, is CRI’s longest-standing continuous program. Fellowships
provide support to fund and train young immunologists and cancer immunologists at top universities and research centers around
the world. Fellows receive up to $164,500 over three years to cover the cost of stipend or salary, insurance, and other researchrelated expenses, such as travel to conferences and meetings. Fellows work and continue their training under the guidance of a worldleading immunologist, who mentors the fellow and prepares him or her for a productive and successful career in cancer immunology.
In fiscal year 2013, the Cancer Research Institute awarded 22 fellowships to postdoctoral investigators, representing a new
commitment of $3.6 million.
INVESTIGATOR AWARD PROGRAM
The Investigator Award Program, established in 1986 to complement our fellowship program, supports accomplished assistant
professors who are undertaking their first independent investigations in basic and tumor immunology. By awarding these researchers
$50,000 per year for four years, the program provides flexibility and a degree of stability during this very challenging period in an
academic scientist’s career. A panel selects recipients based on the applicant’s entire body of research, rather than on a single
project. In fiscal 2013, CRI provided ongoing grant support to 14 investigators in the U.S., Japan, and the United Kingdom.
CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP)
The Clinic and Laboratory Integration Program (CLIP) supports qualified scientists who are working to explore clinically relevant
questions aimed at improving the effectiveness of cancer immunotherapies. The program funds basic, preclinical, and translational
research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants provide up to $200,000
over four years. In fiscal 2013, CRI awarded 8 new CLIP grants totaling $1.6 million.
COORDINATED CANCER INITIATIVES
This program provides a proactive and flexible way for CRI to focus on research areas that are deemed able to provide clinically
relevant insights and discoveries that could potentially accelerate the development of effective cancer immunotherapies. Efforts
within the CCI are currently centered on ovarian, pediatric, and prostate cancers, and multiple myeloma. In fiscal year 2013,
CRI continued to support 4 projects in the U.S. and France.
CRI-funded scientists at work conquering cancer. (Left to right) Dr. Darrell J. Irvine and Dr. Li Tang; Dr. Vanja Sisirak; and Dr. Corrie Painter.
CLINICAL ACCELERATOR
The Clinical Accelerator is an actively managed venture philanthropy program designed to speed the development of cancer
immunotherapies. The strategy facilitates research collaboration across leading biopharma companies and among 50 of the world’s
top cancer researchers. The program aims to identify and kick-start development of next generation combination treatments using the most promising drugs from disparate companies. Each philanthropic investment brings a new cancer treatment to patients,
empowers academic researchers to work more closely with industry, and creates the potential for significant future returns on investment back to CRI to make the venture fund self-sustaining. Launched in mid-2012, the program has created partnerships with or is
finalizing terms with more than 15 of the field’s top companies. Four core resources empower the Clinical Accelerator:
•
COORDINATED NETWORK OF RESEARCHERS
The Cancer Vaccine Collaborative (CVC) Trials Network, managed jointly by the Cancer Research Institute and Ludwig Cancer
Research, is a coordinated global network of nearly 50 clinical investigators with special expertise in immunology. Investigators conduct parallel early-stage clinical trials to identify the optimal composition of successful cancer immunotherapy
combinations, and guide the selection of therapeutic agents and trials.
•
NONPROFIT VENTURE FUND
CRI’s venture fund is designed to speed clinical development of promising cancer immunotherapies. It provides nonprofit
investment capital to incentivize companies to provide the CVC Trials Network with access to proprietary drugs that the CVC
Scientific Advisory Committee has prioritized for clinical testing. Future commercial successes resulting from these trials are
tied to milestone payments back to the nonprofit fund, enabling it to become self-sustaining over time.
•
CLINICAL TRIALS MANAGEMENT
Our partner, Ludwig Cancer Research, sponsors and manages trials conducted with the CVC Trials Network. Their expert
services include study design and set-up, regulatory sponsorship, medical monitoring, drug safety, data capture and
processing, and clinical study reports and analyses.
•
PORTFOLIO OF BIOPHARMA PARTNERSHIPS
Through agreements with biotech and pharmaceutical leaders in the cancer immunotherapy space, the CVC Trials Network
gains access to top immunotherapies. By providing a menu of promising drugs and permitting CVC investigators to combine
drugs owned by disparate companies, these partnerships allow clinical data on new combinations to be generated in advance
of and independent of any commercial transactions between the owners, circumventing an often laborious negotiation process
and thus accelerating clinical research of immunotherapy combinations.
In fiscal year 2013, CRI provided more than $8.7 million to support clinical trials, immunological monitoring activities, and
reagent production and procurement through the Clinical Accelerator program. Also in fiscal year 2013, CRI and Ludwig Cancer
Research announced a partnership with AstraZeneca/MedImmune; the company is providing the CVC Trials Network with access
to three of its highly promising immunotherapeutic drugs. The first trial from this partnership launched in the fourth quarter of
calendar year 2013.
To learn more about the Clinical Accelerator, visit www.cancerresearch.org/accelerator.
CANCER RESEARCH INSTITUTE | 7
MISSION AND MAJOR PROGRAMS (continued)
CANCER IMMUNOTHERAPY CONSORTIUM (CIC)
The Cancer Immunotherapy Consortium (CIC) is an international association of pharmaceutical and biotechnology companies and
academic institutions that share a common interest in immunotherapy research and development. CIC scientists and clinicians,
industry leaders, and governmental regulatory representatives interact and collaborate with one another toward the mission of
making cancer immunotherapies part of the standard-of-care in oncology. Founded in 2002, the CIC offers its members the best
academic and industry expertise in the immunotherapy field. Through annual conferences, member communications, and coordinated
research initiatives, the CIC addresses the networking, clinical, and regulatory needs of academic scientists, corporations, and
organizations working in this promising area of biomedicine. The efforts of the CIC provide data-driven solutions to scientific and
developmental challenges and help to validate and accelerate the development and approval of effective cancer immunotherapies.
To view a current list of members and description of activities, go to www.cancerresearch.org/cic. In fiscal 2013, CRI continued to
fund central laboratory services supporting activities of the ImmunoAssay Proficiency Panels Program, and hosted the annual CIC
Colloquium (see conferences and meetings, below).
GRANTS AND PATIENT SUPPORT
These grants support research projects and public education and awareness initiatives for which, in most cases, donors have
specifically raised funds. In fiscal 2013, CRI awarded $405,000 through this program.
EDUCATIONAL PROGRAMS
CONFERENCES AND MEETINGS
CRI hosts two primary annual conferences designed to bring together leaders in the field to discuss latest data, current scientific
questions, and future directions, as well as to discuss ongoing challenges to cancer immunotherapy development and seek
solutions to these challenges through consensus-building dialogue from multiple stakeholders representing various disciplines
and interests.
•
ANNUAL INTERNATIONAL CANCER IMMUNOTHERAPY SYMPOSIUM
Established in 1993, this series of annual meetings focuses on progress in cancer immunology with special focus on cancer
vaccine and antibody research. In fiscal year 2013, CRI hosted the 20th Annual Meeting in this series, titled, “From Milestones to
Medicines: Translating Tumor Immunology Research into Immunotherapies.” More than 360 students, postdoctoral fellows, and
investigators from more than 70 academic institutions and biopharmaceutical companies attended the meeting, which was
dedicated to the late Dr. Lloyd J. Old, under whose leadership the series was founded. The meeting also included a poster
session with presentations by nearly 130 scientists, six of which were invited to deliver a lecture during the general session.
•
ANNUAL SCIENTIFIC COLLOQUIUM OF THE CRI CANCER IMMUNOTHERAPY CONSORTIUM
CRI organizes annual meetings of the Cancer Immunotherapy Consortium, providing a forum for industry and academic
leaders in cancer immunotherapy research and development. In fiscal year 2013, CRI hosted the 14th Annual Scientific
Colloquium titled, “Entering the Era of Combination Therapies: Practical Implementation.” The meeting brought together
leaders from the regulatory, scientific, and business communities to present new methodological tools, leading-edge scientific
data from ongoing combination studies, and innovative models of academic-industry collaboration that are helping to
overcome challenges to optimizing combination cancer therapies for the benefit of patients.
Scenes from the 2013 CRI Symposium, October 1-3, 2012, New York City
ANNUAL AWARDS
In addition to providing financial support to researchers and investigators, CRI also honors scientists and community leaders
with achievement awards.
•
WILLIAM B. COLEY AWARD FOR DISTINGUISHED RESEARCH IN BASIC AND TUMOR IMMUNOLOGY
CRI grants the Coley Award annually to one or more scientists whose discoveries in the fields of immunology or tumor immunology
contribute to the advancement of immune system-based therapies for cancer. CRI established the award in 1975 in honor
of Dr. William B. Coley, the acknowledged “Father of Cancer Immunotherapy,” whose daughter, Helen Coley Nauts (19072001), founded the Cancer Research Institute.
•
OLIVER R. GRACE AWARD FOR DISTINGUISHED SERVICE IN ADVANCING CANCER RESEARCH
CRI’s Grace Award annually recognizes the contributions of dedicated laypersons whose leadership has had a significant
impact on cancer research. The award is named in memory of Oliver R. Grace (1909-1992), the founding chairman of CRI,
whose vision, leadership, wisdom, and generosity guided and continues to benefit the Institute.
•
FREDERICK W. ALT AWARD FOR NEW DISCOVERIES IN IMMUNOLOGY
The Alt Award honors a former postdoctoral fellow in recognition of outstanding success in academia or industry for research
that may have a potentially major impact on immunology. The award is named after CRI Scientific Advisory Council member
Frederick W. Alt, Ph.D., who not only has made many seminal contributions to the field of immunology, but also has mentored
generations of young scientists.
•
AACR-CRI LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY
Named in honor of CRI’s founding scientific and medical director, the AACR-CRI Lloyd J. Old Award in Cancer Immunology,
funded in partnership with the American Association for Cancer Research, recognizes an active scientist whose outstanding
and innovative research in cancer immunology has had a far-reaching impact on the cancer field.
•
HELEN COLEY NAUTS SERVICE AWARD
This award honors individuals who have made significant contributions of time, energy, and service to CRI. The award
is named in memory of CRI’s founder, Helen Coley Nauts, who dedicated her life to advancing immune system-based
therapies for cancer.
In fiscal year 2013, CRI presented five Coley Awards, two Grace Awards, one Alt Award, and one Old Award. Coley Award winners
each receive a gold medallion and a $5,000 cash prize and are invited to give a plenary lecture at CRI’s annual cancer immunotherapy symposium. Old Award winners receive a $10,000 prize and are invited to give a lecture at the AACR annual meeting.
CANCER RESEARCH INSTITUTE | 9
2013 NOTABLE RESEARCH ACHIEVEMENTS
We are proud to include a list of our major research
accomplishments celebrated over the past year. These
achievements would not have been possible without the
longstanding support and dedication of our generous donors.
CRI STaRT fellow Bryan D. Choi, working in the lab of John
Sampson at Duke University Medical Center, Durham, NC, has
developed a novel potential treatment of glioblastoma (GBM),
the most common and most aggressive primary malignant
tumor of the brain. Reporting their results in Proceedings
of the National Academy of Sciences (PNAS), Choi and
colleagues have shown that a novel type of antibody called
a “bispecific T cell engager” (BiTE) can induce dramatic
tumor regressions in mice, with little apparent toxicity. The
BiTE targets a mutated form of the epidermal growth factor
receptor (EGFRvIII) found on the surface of GBM cells but not
on normal tissues; once bound to their target, the antibodies
trigger a cytolytic (cell-killing) T cell response. The treatment
is able to eradicate tumors in what is often thought to be the
“immunologically privileged” site of the brain, separated from
the bloodstream by the blood-brain barrier.
Diane Tseng, M.D., Ph.D., a CRI STaRT fellow, and colleagues at
Stanford University School of Medicine, Stanford, CA, have
documented a role for CD47 blocking antibodies in cancer
treatment. CD47 is a “don’t eat me” signal; cells expressing this
signal are not eaten by the roving immune cells called macrophages
whose job it is to engulf infected or malignant cells. Tseng’s team
has shown that malignant cancer cells universally express
this signal, and that antibodies targeted to CD47 can increase
phagocytosis (engulfment) of tumor cells by macrophages. In
more recent work, they have shown that anti-CD47 antibodies
can also increase antigen presentation by macrophages,
thus triggering an adaptive immune response resulting in
the activation of cytotoxic “killer” T cells. These results, the
researchers suggest, “might open up a whole new field of
personalized immunotherapy for the treatment of all cancers.”
Lisa C. Osborne, Ph.D., a CRI postdoctoral fellow at the University
of Pennsylvania, Philadelphia, PA, has generated a set of tools
that has increased our understanding of where and how viruselicited T cells behave in the intestinal tract. These tools, which
were recently featured as a Spotlight in the Journal of Virology,
establish a strong foundation for her ongoing research program
and will enable the investigation of the mechanisms responsible
for virus recognition, clearance, and establishment of anti-viral
immunity. Her current studies investigate how helminth-induced
immunomodulatory molecules regulate anti-viral immunity. These
findings may be informative for tumor immunotherapy as well,
based on evidence that the presence of alternatively activated
macrophages is associated with decreased tumor-specific T cell
killing. Ultimately, these findings may provide novel insights into
intestinal anti-viral immunity that will aid in the development of
new therapies to target enteric viral infections.
Georg Gasteiger, M.D., a CRI postdoctoral fellow at Memorial
Sloan-Kettering Cancer Center, New York, NY, discovered a previously
unknown role for regulatory T cells (Tregs) in restraining the
activation of natural killer (NK) cells—a powerful class of cells
that patrol the body and kill cancerous and infected cells. NK
cells are known to accumulate during systemic autoimmunity and
chronic infection, as well as in tumors and the lymphoid organs
of tumor-bearing mice; they also accumulate in human patients
suffering from chronic inflammation and cancer. In two recent
papers published in the Journal of Experimental Medicine, Dr.
Gasteiger reported that Tregs suppress a specific subset of NK
cells by limiting the availability of the cytokine IL-2, produced by
helper T cells. Understanding the mechanisms that control NK
activation and suppression may suggest ways to increase the
effectiveness of immunotherapies by preventing the suppression of
cytotoxic cells without at the same time inducing autoimmunity.
Mickael Menager, Ph.D., a CRI postdoctoral fellow at NYU
Langone Medical Center, New York, NY, is investigating the
possible role of dendritic cells in providing a reservoir for HIV-1
that helps the virus to spread and encourage an environment of
immunosuppression. Using a multidirectional approach, Menager
and colleagues identified several different pathways that will
provide important insights into how HIV exploits dendritic cells
to better infect CD4+ T lymphocytes. In combination with the
laboratory’s published results on dendritic cells’ sensing of HIV,
this approach could help to evaluate the importance of this
process in infected individuals and provide new tools and targets
for the design of therapies that limit viral replication or boost
innate immune responses to control HIV dissemination.
Jeffrey Chou, M.D., Ph.D., a CRI postdoctoral fellow at the
Fred Hutchinson Cancer Research Center in Seattle, WA, is
pursuing research aimed at making colorectal cancer (CRC) more
susceptible to treatment with immunotherapy. One obstacle
that has hindered the progress of immunotherapy for CRC is the
lack of suitable targets (antigens) that are present on CRC cells
but not on normal, noncancerous cells. Chou and colleagues
have found that treatment of CRC cells with the cancer drug
decitabine causes them to begin to express the tumor-specific
antigen NY-ESO-1. They have genetically engineered T cells from
the blood of a patient with metastatic CRC to specifically target
this antigen. They have also, in the process, developed a valuable
method for propagating specific CRC tumor cell lines by growing
them in mice, thus solving an issue of supply for further research.
John T. Wilson, Ph.D., CRI postdoctoral fellow at the University of
Washington School of Medicine, Seattle, WA, obtained evidence
that a new class of vaccine carriers involving “smart” polymers
to deliver cancer antigens and adjuvants to the immune system
improves immune responses compared to antigen and adjuvant
delivered without the “smart” polymer. The results, which were
recently reported in the journal ACS-NANO, provide important
validation for this new vaccine strategy, which Dr. Wilson is now
testing in preclinical models of breast cancer using the Her2/neu
tumor antigen.
CRI postdoctoral researcher Ingunn Stromnes, Ph.D., of the
University of Washington School of Medicine, Seattle, WA, is
developing an immunotherapeutic approach to the treatment
of pancreatic ductal adenocarcinoma (PDA), the fourth leading
cause of cancer-related mortality in the United States. Called
adoptive immunotherapy, the approach involves genetically
engineering a person’s own T cells with T cell receptors designed
to recognize specific antigens present on pancreatic tumor cells.
Stromnes’s team has already used similar methods in patients
with leukemia and lung cancer, and their present work makes
use of a mouse model of PDA that “faithfully recapitulates the
cardinal features of the human disease” as a first step toward
developing the therapy for use in a human clinical trial.
Liang Zhou, M.D., Ph.D., a CRI investigator at Northwestern
University, Evanston, IL, has conducted research that may shed
light on how environmental pollutants such as second-hand smoke
as well as chemicals in food and the air can lead to autoimmune
diseases and cancer. A variety of these foreign chemicals, such
as the carcinogen dioxin, can bind to a receptor on T cells called
the aryl hydrocarbon receptor (Ahr), which seems to function as
an environmental sensor. Why cells would possess a receptor
that binds to man-made pollutants was mysterious, however. In a
recent article to be published in the journal Immunity, Zhou and
colleagues propose that one of the physiological functions of Ahr
in the immune system is to act as a sensor for microbes in the
gut, enabling clearance of pathogens such as Citrobacter rodentium.
Better understanding of the role of Ahr may prove beneficial to
the treatment of autoimmunity and cancer.
Diane Tseng, M.D., Ph.D., a CRI STaRT fellow
Changchun Xiao, Ph.D., a CRI investigator at The Scripps
Research Institute, La Jolla, CA, has generated a mouse model
in which a miR-17~92 (a micro RNA cluster) transgene can
be turned on conditionally in a cell type-specific manner. The
miR-17~92 cluster is known to be highly expressed in cancer
cells, but the mechanisms of action of this microRNA in cancer
and lymphocyte development are largely unknown. The effects of
turning on the transgene in both B and T lymphocytes were tested
in a large cohort of mice, about two-thirds of which developed B cell
lymphoma. These results show that dysregulation of miR-17~92
expression is sufficient to cause cancer, and suggest that this
defect may be one of the primary triggers of human lymphoma.
The role of miR-17~92 in autoimmune disease is also being
explored by Xiao’s team.
A major challenge to the success of T cell-based adoptive
immunotherapy is the deletion (removal) of the transplanted
T cells or induction of T cell tolerance (non-responsiveness)
upon infusion into patients. Using a preclinical model of
adoptive immunotherapy, Ryan M. Teague, Ph.D., a CRI
investigator at Saint Louis University School of Medicine,
St. Louis, MO, discovered that T cell survival and function
could be rescued by administration of antibodies against the
co-inhibitory molecules CTLA-4, PD-1, and LAG-3, providing
durable immunotherapy for advanced leukemia. Moreover, he
found that each receptor had a distinct inhibitory role in the
process. Blockade of PD-1 and CTLA-4 combined to prevent
deletion of adoptively transferred tumor-reactive T cells. The
additional blockade of LAG-3, which had no impact when
administered alone, was vital for restoring effector function
in these surviving T cells. Importantly, this “triple-blockade”
strategy was significantly more effective than any single- or
double-blockade regimen, providing a strong rationale for
strategies targeting multiple checkpoint blockade pathways to
enhance T cell immunotherapy. Teague and colleagues recently
published these results in the journal Cancer Research.
Additional investigations to uncover the signaling molecules
involved in these T cell changes are currently under way.
Ingunn Stromnes, Ph.D., CRI postdoctoral fellow
Ryan M. Teague, Ph.D., a CRI investigator, with members of his lab
CANCER RESEARCH INSTITUTE | 11
2013 NOTABLE RESEARCH ACHIEVEMENTS (continued)
Peter Savage, Ph.D., a CRI investigator at the University of
Chicago, Chicago, IL, obtained the first direct insight into the
basic biology of tumor-infiltrating regulatory T cells in a model
of prostate cancer. Regulatory T cells (Tregs) are thought to pose
a challenge to cancer immunotherapy because of their role in
suppressing anti-cancer immune responses. However, the basic
biology of tumor-associated Tregs—where they originate, which
antigens they recognize, and their function within the tumor—
has not been elucidated. To address these questions, Dr. Savage
established a new model system, allowing him to track the life
cycle of a tumor-associated Treg, from its origin to its circulation
throughout the body to its recruitment into a developing tumor.
Unexpectedly, he found that the antigen recognized by the
population of Tregs he followed was not a cancer-specific antigen,
but rather a normal, prostate-associated antigen. Moreover, he
found that even though prostate tissue is specific to males, Tregs
specific to this antigen develop in both male and female mice.
Savage has shown that Tregs develop in the thymus, and that
this development is dependent on the transcription factor Aire.
Aire, for autoimmune regulator, was originally identified as the
protein that helps create an immunological “self shadow” of
body antigens in the thymus, allowing for elimination of self-reaction
T cells. With this work, Dr. Savage has provided the first direct
evidence that Aire is also critical for the development of Tregs
against naturally occurring antigens. These fundamental discoveries
were recently reported in the prestigious journal Science.
immunotherapies that target the TNF family of receptors in
patients with multiple types of cancer.
CLIP investigator Robert D. Schreiber, Ph.D., has shown how
a novel laboratory technique called ‘exome sequencing’ can
rapidly identify previously unknown cancer antigens (the
specific molecular fingerprints on cancer cells that make them
identifiable to the immune system). Schreiber, a professor
of pathology at Washington University School of Medicine
in St. Louis, MO, is a leading expert on the phenomenon of
immunoediting—the Darwinian selection process whereby
the immune system sculpts a growing tumor, leading to the
emergence of cancer cells with the ability to escape immune
detection. His lab has successfully used exome sequencing
to identify unique tumor-specific antigens in tumors, even
after they have been sculpted by the immune system.
Exome sequencing thus has the potential to reveal new
targets for cancer immunotherapy and paves the way toward
individualized vaccination against cancer.
Research by Dimitrios Iliopoulos, Ph.D., a CRI investigator at
the University of California, Los Angeles, Los Angeles, CA, has
identified microRNA-214 (miR-214) as a specific marker for
ulcerative colitis-associated colon cancer development, but not
spontaneous colon cancer. According to Dr. Iliopoulos, miR-214
is the first marker that is able to characterize and distinguish
inflammation-associated colon cancers relative to sporadic colon
cancers, which could have important clinical implications. Future
experiments will reveal if miR-214 can predict which ulcerative
colitis patients are at higher risk for developing colon cancer. In
addition, Dr. Iliopoulos plans to evaluate if inhibition of miR-214
could have therapeutic potential for colon cancer patients with a
history of ulcerative colitis.
Jedd D. Wolchok, M.D., Ph.D., director of CRI’s clinical program,
generated a flurry of excitement at the 2013 American Society
of Clinical Oncology (ASCO) meeting when he presented results
of an ongoing phase 1 trial of two Bristol-Myers Squibb-owned
antibodies, ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).
Both drugs are designed to turn off certain “brakes” that can
stop an immune response against cancer. The two antibodies
are being used in combination as a novel treatment for patients
with a deadly form of melanoma that typically has an 80%
5-year mortality rate. More than 50% of patients with advanced
melanoma who were treated at the best-responding dose had
an 80% reduction in the size of their tumors by their first
assessment (at or around week 12), and more than 90% of all
responding patients continued to respond after 13 months. These
exciting results help to validate the promise of immunotherapy—
especially the use of multiple drugs in combination—and
underscore the wisdom of CRI’s Clinical Accelerator program,
which brings together the unique strengths of the for-profit
and nonprofit sectors to speed up development of promising
immunotherapies for the benefit of patients.
In recent papers published in Proceedings of the National
Academy of Sciences (PNAS) and Cell Cycle, CLIP investigator
Jeffrey Ravetch, M.D., Ph.D., of The Rockefeller University, New
York, NY, presented research that promises to improve the tumorkilling activity of anti-CD40 antibodies. CD40, a member of the
tumor necrosis family of receptors, is found on various cells in the
immune system; when stimulated, CD40 can trigger an immune
response by tumor-specific T cells. Antibodies to CD40 (antiCD40) have shown great promise in preclinical models, but have
so far failed to reap significant rewards in the clinic. Ravetch’s
work helps explain why: maximum activation of CD40 requires
the “co-engagement” of another receptor, called inhibitory Fcγ,
but existing anti-CD40 antibodies do not bind this receptor.
Ravetch’s lab is using transgenic technology to engineer new
therapeutic antibodies that bind to both CD40 and the Fcγ
receptor, for improved tumor killing. This work has the potential
to greatly improve the clinical efficacy of antibody-based
CRI Scientific Advisory Council associate director Robert D. Schreiber, Ph.D.
FISCAL YEAR 2013 GRANTS & AWARDS
In fiscal year 2013 (July 1, 2012, to
June 30, 2013), CRI awarded more
than $14.6 million for cancer immunology
research and cancer immunotherapy
clinical development at more than 30
research centers worldwide.
University of California, Berkeley,
Berkeley, CA
Thornton William Thompson*
The role of oncogene-induced
senescence in promoting anti-tumor
immune responses
* Denotes grants newly awarded in
fiscal 2013. All others are active grants
awarded in previous years.
PREDOCTORAL EMPHASIS PATHWAYS
IN TUMOR IMMUNOLOGY
RESEARCH PROGRAMS
STUDENT TRAINING AND RESEARCH IN
TUMOR IMMUNOLOGY (START) PROGRAM
Duke University Medical Center,
Durham, NC
Bryan D. Choi
EGFRvIII-targeted bispecific antibody
therapy for malignant glioma
Harvard Medical School, Boston, MA
Jenna Elizabeth Geddes
Analyzing the efficacy of galectin-1
ligand inhibition in adoptive T cell
therapy
Massachusetts General Hospital,
Boston, MA
Alexandria Huynh*
The role of PTEN in regulatory T cell
stability and immune surveillance
Memorial Sloan-Kettering Cancer Center,
New York, NY
Jenny Karo*
Elucidating the regulatory role of CTLA4 on natural killer cell responses
Harvard Medical School, Boston, MA
Program Directors: Glenn Dranoff, M.D.,
and Shannon J. Turley, Ph.D.
The Johns Hopkins University School
of Medicine, Baltimore, MD
Program Director: Charles G. Drake, M.D.,
Ph.D.
Perelman School of Medicine at
the University of Pennsylvania,
Philadelphia, PA
Program Director: Yvonne Paterson, Ph.D.
Queensland Institute of Medical Research,
Queensland, Australia
Program Director: Mark J. Smyth, Ph.D.
University of Colorado, Denver, CO
Program Directors: John Kappler, Ph.D.,
and Philippa Marrack, Ph.D.
University of Washington School of
Medicine, Seattle, WA
Program Director: Philip D. Greenberg, M.D.
Washington University School of
Medicine, St. Louis, MO
Program Director: Robert D. Schreiber, Ph.D.
Perelman School of Medicine at the
University of Pennsylvania,
Philadelphia, PA
Thomas Chia Ting Fung*
Role of innate lymphoid cellcontrolled intestinal barrier function in
hepatocellular carcinoma
Weill Cornell Medical College,
New York, NY
Program Directors: Alexander Y. Rudensky,
Ph.D., and Carl F. Nathan, M.D.
Albert Lo
Regulation of inflammatory and immune
response to pancreatic cancer by FAP+
stromal cells
Lomonosov Moscow State University,
Moscow, Russia
Course Coordinator: Sergei A.
Nedospasov, Ph.D., D.Sc.
The Lloyd J. Old Advanced Training
Program in Immunology and
Oncoimmunology
Stanford University School of Medicine,
Stanford, CA
Diane Tseng, M.D., Ph.D.
Characterizing the role of anti-CD47 therapy
on antigen presentation in solid tumors
Immunology/Tumor Immunology
Training Course
CRI IRVINGTON POSTDOCTORAL
FELLOWSHIP PROGRAM
Albert Einstein College of Medicine,
Bronx, NY
Vladimir Vigdorovich, Ph.D.
Structure of T cell activation modulatory
signal molecules B7-H3 and B7-H4
Beth Israel Deaconess Medical Center,
Boston, MA
Javier Gordon Ogembo, Ph.D.
Characterization of the littoral cell of
human spleen and identification of its
function in health and disease
Boston Children’s Hospital, Boston, MA
Liron David, Ph.D.
Molecular elucidation of the CBM
complex in NFκB activation by antigen
receptors
Chunguang Guo, Ph.D.
Complementary functions of ATM and
XLF in double strand break repair and
lymphocyte development
Feilong Meng, Ph.D.
Role of cofactors in targeting activationinduced cytidine deaminase activity
during class switch recombination and
somatic hypermutation
Qi Qiao, Ph.D.*
Mechanistic elucidation of activationinduced deaminase in immunity and
cancer
Leng Siew Yeap, Ph.D.
Mechanisms by which DNA sequence
influence AID targeting in antibody
diversity and B lymphocyte cancer
Hye Suk Yoon, Ph.D.*
Elucidation of V(D)J recombination
control elements in the IgH locus
California Institute of Technology,
Pasadena, CA
Hao Yuan Kueh, Ph.D.
Regulatory mechanisms underlying T
cell fate commitment in hematopoietic
progenitors
CANCER RESEARCH INSTITUTE | 13
Blaise Ndjamen, Ph.D.
A model system to investigate antibody
bipolar bridging mediated by gE-gI, a
Herpes virus Fc receptor
Beth M. Stadtmueller, Ph.D.
The structural and molecular basis of
polymeric IgA function in mucosal
immunity and associated cancers
Children’s Hospital and Regional Medical
Center, Seattle, WA
Allison M. De Wispelaere, Ph.D.
Development of regulated transgene
expression switches for enhanced safety
of CAR redirected T cells
Columbia University, New York, NY
Yenkel Grinberg-Bleyer, Ph.D.*
Testing the role of NFκB in tumor
immunity through its effect on
regulatory T cells
Vanja Sisirak, Ph.D.
Novel regulator of DNA recognition
by dendritic cells
Dana-Farber Cancer Institute, Boston, MA
Viviana Cremasco, Ph.D.*
Targeted disruption of tumor matrix
architecture to restore cancer
immunosurveillance
Rajesh R. Rao, Ph.D.
Novel exercise-induced myokines as
modulators of inflammation and defense
against chronic diseases
Emory University, Atlanta, GA
Jin-Hwan Han, Ph.D.
Enhanced anti-tumor immunity by
regulation of IgG sialylation
Alice O. Kamphorst, Ph.D.
Role of dendritic cells in T cell dysfunction
during chronic viral infections
Nicole L. Sullivan, Ph.D.
Development of human CD4+ T cell
memory against viruses
Fred Hutchinson Cancer Research Center,
Seattle, WA
Rupesh H. Amin, Ph.D.
Monoallelic expression of mouse TLR4
as a model for transcriptional memory
Jeffrey Chou, M.D., Ph.D.
Epigenetic modulation for T cell therapy
of colorectal cancer
Matthew D. Daugherty, Ph.D.
Evolution of innate immunity to
oncoviruses: Recognition and inhibition
of human papillomavirus
Michael Kors Fellow
Institut Curie, Paris, France
Yvonne K. Mburu, Ph.D.
Mucosal-associated invariant T cells
in anti-tumor therapy
Lloyd J. Old Memorial Fellow
The Johns Hopkins University School of
Medicine, Baltimore, MD
Ying Zheng, Ph.D.
The role of HIF-1 in adaptive T cell
responses to cancer
Donald J. Gogel Fellow
Jeffrey Ravetch, M.D., Ph.D., CRI CLIP investigator
La Jolla Institute for Allergy and
Immunology, La Jolla, CA
Aparna Gudlur, Ph.D.
Structural studies on the lymphocyte
Ca2+ channel pore-forming protein
ORAI1
Chan-Wang J. Lio, Ph.D.*
Role of long non-coding RNAs in the
development of T cell leukemia
Sara Trifari, Ph.D.
Identification and functional
characterization of novel epigenetic
and transcriptional regulators of CD8+
T cell differentiation
Chan-Wang J. Lio, Ph.D., CRI postdoctoral fellow
Ageliki Tsagaratou, Ph.D.
Dissecting the role of 5 hydroxymethylcytosine in T cell development,
homeostasis, and function
Massachusetts General Hospital,
Boston, MA
Read Pukkila-Worley, M.D.
A novel live-animal system for the
characterization of antifungal innate
immunity
Massachusetts Institute of Technology,
Cambridge, MA
Li Tang, Ph.D.*
T lymphocyte engineering with
interleukin-2-silica nanocapsules
for targeted cancer therapy
Alice O. Kamphorst, Ph.D., CRI postdoctoral fellow
FISCAL YEAR 2013 GRANTS & AWARDS (continued)
Memorial Sloan-Kettering Cancer Center,
New York, NY
Margaret Callahan, M.D., Ph.D.
Immunologic effects of BRAF inhibitors:
Towards the rational development of
multi-modality therapy for advanced
melanoma
Lloyd J. Old Memorial Fellow
Anne Marie Christine Chauveau, Ph.D.
Role of DGKα in cytoskeleton remodeling
and T cell effector functions
Yongqiang Feng, Ph.D.
Role of conserved non-coding
elements of Foxp3 in regulatory
T cell development and function
Bristol-Myers Squibb Fellow
Georg A.J. Gasteiger, M.D.
Regulation of cytotoxic killer cells by
Foxp3+ regulatory T cells
CRI Scientific Advisory Council associate director Jedd D. Wolchok, M.D., Ph.D., in the clinic with team
member and CRI Lloyd J. Old Memorial Fellow Margaret Callahan, M.D., Ph.D.
Jesse Green, Ph.D.*
Interactions of regulatory T cells with
the tumor endothelium and effects on
the tumor microenvironment
Samuel and Ruth Engelberg Fellow
Katharina Kreymborg, Ph.D.
Functional characterization of the new
B7 family members B7-H3 and B7x
and determining their role in tumor
immunology
Young Philanthropists Council Fellow
NYU Langone Medical Center, New York, NY
Julie Chaumeil, Ph.D.
The role of ATM and RAG in maintaining
genome stability during Tcra/d recombination in developing T lymphocytes
Wendy Jia Men Huang, Ph.D.
Molecular mechanisms underlying SFBTh17 induction and intestinal tumor
pathogenesis
Margaret Dammann Eisner Fellow
Sudha Kumari, Ph.D.
Characterization of a novel molecular
compartment modulating regulatory T
cell function
Vivek Mayya, Ph.D.
The role of actin cytoskeleton in
regulating the immunological synapsekinapse balance
Jeffrey Rathmell, Ph.D., with lab members Amanda Nichols and Peter Siska
CANCER RESEARCH INSTITUTE | 15
Mickael Mathieu Menager, Ph.D.
Molecular mechanisms of dendritic
cell-mediated transfer of HIV-1 to CD4+
T lymphocytes
Mo Xu, Ph.D.*
Intestinal microbiota-induced Th17
responses in systemic inflammatory
disease
Joshua W. Ziel, Ph.D.
Commensal control of intestinal Th17:
Treg balance during homeostasis and
carcinogenesis
Perelman School of Medicine at the
University of Pennsylvania, Philadelphia, PA
Lisa C. Osborne, Ph.D.
Regulation of protective immunity
following enteric viral infection
Edmond J. Safra Fellow
The Rockefeller University, New York, NY
Shengdong Ke, Ph.D.*
RNA epigenetic HITS-CLIP: A new
approach to understanding leukemia/
lymphoma
The Scripps Research Institute,
La Jolla, CA
Hui Xiao, Ph.D.
Study of Pallbearer, an E3-ubiquitin
ligase that regulates phagocytosis of
apoptotic cells in Drosophila
Stanford University School of Medicine,
Stanford, CA
Paola A. Betancur, Ph.D.*
In search of the gene regulatory circuitry
responsible for the transcriptional
upregulation of CD47, the ‘don’t eat
me’ signal in cancer cells
John S. Burg, Ph.D.
Structural studies of Wnt receptor
activation
Vincent Christopher Luca, Ph.D.*
Deconstructing the structural mechanisms
of cytokine-mediated JAK activation
University Health Network, Toronto,
Canada
Maureen Ann Cox, Ph.D.*
Investigation of the role of HMGB1
in asbestos-driven inflammation and
mesothelioma development
University of California, Berkeley,
Berkeley, CA
Michele Ardolino, Ph.D.*
MHC-deficient tumors inactivate
infiltrating NK cells: A new target for
cancer immunotherapy
Ivan Lilyanov Dzhagalov, M.D., Ph.D.
Zone for negative selection in the
thymic medulla and the role of AIRE in
their function
April Price, Ph.D.*
Expression and function of Toll-like
receptors in intestinal epithelial cells
Qi Wang, Ph.D.
Molecular mechanisms of T cell
activation by the tyrosine kinase Lck
and ZAP-70
Qingrong Yan, Ph.D.
Mechanism of immune regulation by
the zap-70/syk tyrosine kinase family
University of California, San Diego,
La Jolla, CA
Malina A. Bakowski, Ph.D.
Innate immunity and microsporidia
pathogenesis in the nematode C.
elegans
James A. Harker, Ph.D.
The role of gp130-associated cytokines
in chronic viral infection
Chunyu Jin, Ph.D.
Genomic approaches to roles of GPS2
in innate immunology dependent events
in prostate cancer
Yina Zhu, Ph.D.*
Mechanisms that underpin the
sequestration of the tumor suppressor
ebf1 at the nuclear lamina
University of California, San Francisco,
San Francisco, CA
Diego Acosta-Alvear, Ph.D.
Regulation of the unfolded protein
response in multiple myeloma
Lingfeng Liu, Ph.D.
Optimizing T cells for cancer therapy:
A synthetic biology approach
Boryana N. Manz, Ph.D.
Negative regulation of SFK and Ras
by Dok1
Andrea Reboldi, Ph.D.
Analysis of antigen uptake and B cell
activation in Peyer’s patches
Xiaolei Su, Ph.D.*
Mechanisms underlying the dynamic
organization of T cell microclusters
Jared E. Toettcher, Ph.D.
Variable input stimulation: Using
engineering approaches to interrogate
dynamics and feedback in T cell
signaling
Tangsheng Yi, Ph.D.
Role of EBI2 and its oxysterol ligands in
adaptive immunity
University of Cambridge, Cambridge,
United Kingdom
James Arnold, D.Phil.
Immunosuppressive mechanisms of
mesenchymal cells and the therapeutic
vaccination of cancer
University of Maryland, College Park, MD
Xin Xiang Wang, Ph.D.
Use of directed evolution to assemble
TCR-MHC-CD4 and TCR-CD3 complexes
for X-ray crystallographic analysis
University of Massachusetts Medical
School, Worcester, MA
Corrie Ann Painter, Ph.D.
Investigating the adaptive immune
response to melanoma in the zebrafish
Danio rerio
University of Michigan Medical School,
Ann Arbor, MI
Sakie Hosoya-Ohmura, Ph.D.
Integration of the transcriptional
network that regulates Gata3 during T
lymphocyte development
University of Minnesota, Minneapolis,
Minneapolis, MN
Ross B. Fulton, Ph.D.
Naïve CD8+ T cells differ in their ability
to respond to tumor-associated antigen
You Jeong Lee, M.D., Ph.D.
IL-4 produced by iNKT cells directs the
development of memory CD8+ T cells
Justin J. Taylor, Ph.D.
Direct tracking of vaccine-specific B
cells from naïve precursors
FISCAL YEAR 2013 GRANTS & AWARDS (continued)
University of North Carolina at Chapel Hill,
Chapel Hill, NC
Timothy Eitas, Ph.D.
Regulation of colitis-associated cancer
by NLRX1
Haitao Wen, Ph.D.
The role and mechanism of Plexin-A4
in colitis-associated cancer
University of Oxford, Oxford, United Kingdom
Nathan Richard West, Ph.D.
Analysis of novel susceptibility genes
in chronic intestinal inflammation and
colon cancer
Dimitrios Iliopoulos, Ph.D., CRI investigator at the
University of California, Los Angeles
University of Washington School of
Medicine, Seattle, WA
Tessa Bergsbaken, Ph.D.
A T cell intrinsic role for Caspase-1
in the immune response
Elizabeth Gray, Ph.D.*
Functional analysis of the interferon
stimulatory DNA pathway
Andrea Schietinger, Ph.D.
Re-programming tolerant CD8+ T cells
specific for self antigens to improve
cancer immunotherapy
Ingunn Margarete Stromnes, Ph.D.
T cell therapy of pancreatic cancer targeting
normal and oncogenic antigens
John Tanner Wilson, Ph.D.
A new class of multifunctional smart
polymers for cancer vaccine delivery
Nina Bhardwaj, M.D., Ph.D., Wade F. B. Thompson
CLIP Investigator at Mount Sinai School of Medicine
Weill Cornell Medical College,
New York, NY
Juan R. Cubillos-Ruiz, Ph.D.
XBP1 as a key regulator of dendritic
cell pro-tumoral activity
Johanna Napetschnig, Ph.D.
Structural and biochemical elucidation
of the membrane proximal events in
Toll-like receptor signaling
Whitehead Institute for Biomedical
Research, Cambridge, MA
Giulia Pasqual, Ph.D.*
In vivo tracking of B cell-T cell
interactions in the germinal center
Yale University School of Medicine,
New Haven, CT
Nicola Gagliani, Ph.D.*
Targeting Th17 cell plasticity to control
colorectal cancer development
Dr. Keith Landesman Memorial Fellow
Jeffrey E. Grotzke, Ph.D.
Membrane receptors and associated
signaling pathways in cross presentation
Kiwook Kim, Ph.D.*
GBP5-NOD2 interactions in gastrointestinal
host defense, colitis, and colon cancer
James B. Munro, Ph.D.
Single-molecule imaging of immune
evasion by HIV Env
Noah Wolcott Palm, Ph.D.*
Role of helminth infections and the
commensal microbiota in intestinal
inflammation
Debrup Sengupta, Ph.D.*
Membrane trafficking events regulating
cross presentation
Grace Teng, Ph.D.
Genome-wide mapping of RAG1 and
RAG2 protein binding
INVESTIGATOR AWARDS
Fred Hutchinson Cancer Research Center,
Seattle, WA
Jennifer M. Lund-Friesen, Ph.D.
Regulatory T cell modulation of
immunity to mucosal viral infections
Harvard School of Public Health,
Boston, MA
Wendy S. Garrett, M.D., Ph.D.
The role of inflammatory monocytes and
the gut microbiota in colorectal cancer
Massachusetts General Hospital,
Boston, MA
Shobha Vasudevan, Ph.D.
Translation regulation of IL1 by AREs
and microRNAs in leukemia
Memorial Sloan-Kettering Cancer Center,
New York, NY
Joseph C. Sun, Ph.D.
Natural killer cell responses against
cancer and infectious disease
CANCER RESEARCH INSTITUTE | 17
Northwestern University, Evanston, IL
Liang Zhou, M.D., Ph.D.
Molecular mechanisms of action of Ahr
in T cell differentiation and function
NYU Langone Medical Center,
New York, NY
Susan R. Schwab, Ph.D.
Sphingosine-1-phosphate distribution
and immunity
Osaka University, Osaka, Japan
Hiroyoshi Nishikawa, M.D., Ph.D.
Development of cancer immunotherapy
targeting regulatory T cells
Saint Louis University School of Medicine,
St. Louis, MO
Ryan M. Teague, Ph.D.
Overcoming obstacles for improved
adoptive T cell immunotherapy
The Scripps Research Institute,
La Jolla, CA
Changchun Xiao, Ph.D.
The role of miR-17~92 in the immune
system and during lymphomagenesis
University College London, London,
United Kingdom
Sergio A. Quezada, Ph.D.
Mechanisms underpinning the function
of regulatory and effector tumor-reactive
CD4+ T cells during tumorigenesis and
cancer immunotherapy
University of California, Los Angeles,
Los Angeles, CA
Dimitrios Iliopoulos, Ph.D.
Identification of novel molecular circuits
that link inflammation to cancer
University of California, San Francisco,
San Francisco, CA
Jeoung-Sook Shin, Ph.D.
Mechanism and function of ubiquitinmediated membrane traffic in dendritic
cells
University of Chicago, Chicago, IL
Peter A. Savage, Ph.D.
Endogenous CD4+ regulatory T cell
and CD8+ T cell responses in a mouse
model of autochthonous prostate cancer
University of Medicine and Dentistry of
New Jersey-Robert Wood Johnson Medical
School, Piscataway, NJ
Estela P. Jacinto, Ph.D.
mTOR targets in T lymphocyte
development
CLINIC AND LABORATORY INTEGRATION
PROGRAM (CLIP)
Austin Health/Ludwig Cancer Research,
Victoria, Australia
Jonathan S. Cebon, Ph.D., FRACP*
Evaluation of ROPN and SPANX as targets for antigen-specific immunotherapy
Wade F. B. Thompson CLIP Investigator
Duke University Medical Center,
Durham, NC
Jeffrey C. Rathmell, Ph.D.*
Metabolic immunosuppression of T cells
in clear cell renal cell carcinoma and
anti-PD-1 therapy
Wade F. B. Thompson CLIP Investigator
Memorial Sloan-Kettering Cancer Center,
New York, NY
Ming O. Li, Ph.D.
The Adrb-cAMP-ICER pathway in control
of mammary tumor immune evasion
Mount Sinai School of Medicine,
New York, NY
Nina Bhardwaj, M.D., Ph.D.*
MMP-2 promotes melanoma progression
through TLR-mediated mechanisms
Wade F. B. Thompson CLIP Investigator
Osaka University, Osaka, Japan
Hiroyoshi Nishikawa, M.D., Ph.D.*
Novel cancer immunotherapy targeting
regulatory T cells by anti-CCR4 mAb
Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands
Gosse J. Adema, Ph.D.
Exploiting in situ tumor destruction
techniques for the in vivo modulation of
anti-tumor immunity
The Rockefeller University, New York, NY
Jeffrey V. Ravetch, M.D., Ph.D.
Enhancing the immunotherapeutic
activity of anti-CD40 antibodies
University of Chicago, Chicago, IL
Thomas F. Gajewski, M.D., Ph.D.*
Identification of tumor-intrinsic
signaling pathways that inhibit host immune
CRI investigator Peter A. Savage, Ph.D., at the
University of Chicago, is studying the responses of
regulatory and CD8+ T cells in prostate cancer.
responses as potential therapeutic
targets to expand the applicability
of immunotherapy
Oliver R. Grace CLIP Investigator
University of Pennsylvania School of
Veterinary Medicine, Philadelphia, PA
Ellen Puré, Ph.D.*
Adoptive T cell therapy targeted to
tumor stroma to treat lung cancer
University of Queensland, Queensland,
Australia
Ian Hector Frazer, M.D., FRCPA*
Optimising immunotherapy for
squamous cancer
University of Southern California,
Los Angeles, CA
W. Martin Kast, Ph.D.*
Anti-CTLA-4 immune modulation
following chemoradiation in cervical
cancer patients
Washington University School of
Medicine, St. Louis, MO
Robert D. Schreiber, Ph.D.
A genomics-based approach to
facilitate checkpoint blockade
cancer immunotherapy
COORDINATED CANCER INITIATIVES
Centre de Lutte Contre Le Cancer
Nantes-Atlantique, Nantes, France
Danila Valmori, Ph.D.
Assessment of tumor antigen-specific
FISCAL YEAR 2013 GRANTS & AWARDS (continued)
CD4+ T cells among Tregs and Th17 cells
within TIL/TAL in epithelial ovarian cancer
Mount Sinai School of Medicine,
New York, NY
Hearn Jay Cho, M.D., Ph.D.
Vaccine immunotherapy program in
multiple myeloma
NYU Langone Medical Center,
New York, NY
Sharon Gardner, M.D.
A phase 1 study of peptide vaccination
with tumor-associated antigens mixed
with Montanide ISA-51 VG in patients
with recurrent or refractory central
nervous system disorders
University of Connecticut School of
Medicine, Farmington, CT
Pramod K. Srivastava, M.D., Ph.D.
Genomics-driven identification of true
tumor-specific antigens and their use
in immunotherapy of spontaneous
prostate cancers
CLINICAL ACCELERATOR
Austin Health/Ludwig Cancer Research,
Melbourne, Australia
Jonathan S. Cebon, Ph.D., FRACP
Phase 1 study of NY-ESO-1 vaccine
in combination with ipilimumab in
patients with unresectable or metastatic
melanoma, for whom treatment with
ipilimumab is indicated
Centre de Lutte Contre Le Cancer
Nantes-Atlantique, Nantes, France
Danila Valmori, Ph.D., and
Maha Ayyoub, Ph.D.
Early-phase NY-ESO-1 clinical trials
in patients with epithelial ovarian,
fallopian tube, or primary peritoneal
carcinoma and monitoring of tumorspecific immune responses
Dana-Farber Cancer Institute, Boston, MA
Patrick Ott, M.D., Ph.D.*
Phase 1 study to evaluate the safety and
tolerability of anti-PD-L1 (MEDI4736),
in combination with tremelimumab in
subjects with advanced solid tumors
Fred Hutchinson Cancer Research Center,
Seattle, WA
Philip D. Greenberg, M.D.
Potentiating T cell therapy targeting
NY-ESO-1 with administration of antiCTLA-4
Kawasaki University of Medical Welfare,
Okayama, Japan
Eiichi Nakayama, M.D., Ph.D.
XAGE: A vaccine target for lung cancer
Krankenhaus Nordwest, Frankfurt, Germany
Elke Jäger, M.D.
NY-ESO-1 and mixed bacterial vaccine
clinical trials and immune monitoring
Leiden University Medical Center,
Leiden, The Netherlands
Cornelis J.M. Melief, M.D., Ph.D.
Preclinical toxicity studies to enable
the clinical development of the XAGE1b
peptide vaccine
complete clinical remission; Phase 2
study of CTLA-4 blockade and low dose
cyclophosphomide in patients with
advanced malignant melanoma after
failure of at least one prior therapy
Philip Friedlander, M.D.*
Phase 1 study of NY-ESO-1 vaccine
in combination with ipilimumab in
patients with unresectable or metastatic
melanoma, for whom treatment with
ipilimumab is indicated
Sacha Gnjatic, Ph.D.
Immunological monitoring for the
CVC trials
Université de Lausanne, Lausanne,
Switzerland
Daniel E. Speiser, M.D.
Vaccination of melanoma patients (stage
II-IV) with ImmuFact IMP321, tumor
antigenic peptides, and Montanide®
NYU Langone Medical Center, New York, NY
Anna Pavlick, D.O.
Phase 2 study of CTLA-4 blockade and
low dose cyclophosphomide in patients
with advanced malignant melanoma
after failure of at least one prior therapy
Memorial Sloan-Kettering Cancer Center,
New York, NY
Michael A. Pastow, M.D.
Phase 1 study of NY-ESO-1 vaccine
in combination with ipilimumab in
patients with unresectable or metastatic
melanoma, for whom treatment with
ipilimumab is indicated
Roswell Park Cancer Institute, Buffalo, NY
Kunle Odunsi, M.D., Ph.D.*
Phase 1 study to evaluate the safety and
tolerability of anti-PD-L1 (MEDI4736)
in combination with tremelimumab in
subjects with advanced solid tumors
Jedd D. Wolchok, M.D., Ph.D., and
Margaret Callahan, M.D., Ph.D.*
Defining the importance of immunity to
NY-ESO-1 in melanoma; Phase 1 study
to evaluate the safety and tolerability of
anti-PD-L1 (MEDI4736) in combination with tremelimumab in subjects with
advanced solid tumors
Mie University School of Medicine,
Mie, Japan
Hiroshi Shiku, M.D., and Shinichi
Kageyama, M.D.
Phase 1 studies of vaccination with
different forms of NY-ESO-1 in patients
with esophageal cancer, melanoma,
and/or other advanced cancers that
express NY-ESO-1
Mount Sinai School of Medicine,
New York, NY
Nina Bhardwaj, M.D., Ph.D.
Phase 1/phase 2 open label study of the
TLR3 agonist Poly-ICLC as an adjuvant
for NY-ESO-1 protein vaccination with
or without Montanide® ISA-51 VG in
patients with high risk melanoma in
University Hospital Zürich, Zürich,
Switzerland
Christoph Renner, M.D.
Developing therapeutic strategies for
NY-ESO-1 157-165 / HLA-A2 specific
redirected T cells (T bodies)
University of Oxford, Oxford, United Kingdom
Vincenzo Cerundolo, M.D., Ph.D.
Developing therapeutic strategies for
NY-ESO-1 157-165 / HLA-A2 specific
redirected T cells (T bodies)
University of Pittsburgh Cancer Institute,
Pittsburgh, PA
Hassane M. Zarour, M.D.*
Phase 1 study of NY-ESO-1 vaccine
in combination with ipilimumab in
patients with unresectable or metastatic
melanoma, for whom treatment with
ipilimumab is indicated
University of Virginia Cancer Center,
Charlottesville, VA
Craig L. Slingluff Jr., M.D.*
Phase 1 study of NY-ESO-1 vaccine
in combination with ipilimumab in
CANCER RESEARCH INSTITUTE | 19
patients with unresectable or metastatic
melanoma, for whom treatment with
ipilimumab is indicated
Reagent/Assay Production and Procurement
PolyPeptide Laboratories San Diego*
San Diego, CA
Production of NY-ESO-1 overlapping
peptides for use in a variety of trials
Oncovir, Inc.*
Washington, DC
Poly-ICLC stability testing
Leveraged Grants
CRI/SU2C Cancer Immunology
Translational Research Dream Team
Dream Team Leaders: James P. Allison,
Ph.D., The University of Texas MD
Anderson Cancer Center, Houston, TX,
and Antoni Ribas, M.D., Ph.D.,
University of California, Los Angeles, CA
Immunologic checkpoint blockade and
adoptive T cell transfer in cancer therapy
In partnership with Entertainment
Industry Foundation/Stand Up To Cancer
Perelman School of Medicine at the
University of Pennsylvania, Philadelphia, PA
Carl H. June, M.D., and Gregory L.
Beatty, M.D., Ph.D.
Mesothelin-specific chimeric antigen
receptor (CAR) T cell therapy for pancreatic cancer
In partnership with Lustgarten Foundation
CANCER IMMUNOTHERAPY
CONSORTIUM (CIC)
Duke University Medical Center, Durham, NC
Thomas N. Denny, M.S.C.
Central lab services for the Cancer
Immunotherapy Consortium’s Immune
Proficiency Panel Program
GRANTS & PATIENT SUPPORT
Karolinska Institute, Stockholm, Sweden
George Klein, M.D., D.Sc.*
Studies on Epstein-Barr virus, oncogenes and tumor suppressor genes,
tumor immunology, and inhibition of
tumor cell growth by stroma cells
In partnership with Concern Foundation
Memorial Sloan-Kettering Cancer Center,
New York, NY
Malcolm A.S. Moore, D.Phil.*
The study of hematopoietic stem cells
and progenitor populations in normal
and cancer cells
Gar Reichman Laboratory
ZERO-The End of Prostate Cancer,
Washington, DC
Support of the Drive Against Prostate
Cancer mobile screening vehicle*
Frederick W. Alt Award for New
Discoveries in Immunology
Sebastian Amigorena, Ph.D.*
Institut Curie, Paris, France
AACR-CRI Lloyd J. Old Award in Cancer
Immunology
James P. Allison, Ph.D.*
The University of Texas MD Anderson
Cancer Center, Houston, TX
ANNUAL AWARDS
William B. Coley Award for
Distinguished Research in Basic and
Tumor Immunology
In Basic Immunology
Richard A. Flavell, Ph.D., FRS*
Yale University School of Medicine,
New Haven, CT
Laurie H. Glimcher, M.D.*
Weill Cornell Medical College, New York,
NY
Kenneth M. Murphy, M.D., Ph.D.*
Washington University School of
Medicine, St. Louis, MO
In Tumor Immunology
Dr. Laurie Glimcher receives the 2012 William B.
Coley Award for Distinguished Research in Basic
Immunology from CRI Scientific Advisory Council
director Dr. James P. Allison.
Carl H. June, M.D.*
Abramson Cancer Center, Perelman
School of Medicine at the University of
Pennsylvania, Philadelphia, PA
Michel Sadelain, M.D., Ph.D.*
Memorial Sloan-Kettering Cancer
Center, New York, NY
Oliver R. Grace Award for Distinguished
Service in Advancing Cancer Research
Mark P. Frissora*
Chairman and Chief Executive Officer
Hertz Corporation, Park Ridge, NJ
Dr. Severin Schwan*
Chief Executive Officer
Roche Corporation, Basel, Switzerland
Dr. Carl H. June receives the 2012 William B.
Coley Award for Distinguished Research in Tumor
Immunology from CRI Scientific Advisory Council
associate director Dr. Jedd D. Wolchok.
2013 FINANCIAL SUMMARY
EisnerAmper LLP conducted an independent audit of the Cancer Research Institute’s financial activities for fiscal year 2013
(July 1, 2012, to June 30, 2013).
Our complete audited financial statements are available on our website at www.cancerresearch.org/financials or by request
from CRI at One Exchange Plaza, 55 Broadway, Suite 1802, New York, NY 10006.
REVENUE SOURCES
Contributions (including designated) - $13,876,724
Bequests/Memorials - $2,374,248
Special Events - $1,844,872
Investment Income - $1,674,479
Combined Federal Campaign and Other - $564,995
EXPENSES
TOTAL EXPENSES
RESEARCH EXPENSES
Program
Services
- 86%
Program
Services
- 86%
Marketing
& Development
- 8%
Marketing
& Development
Administration
- 6%
Administration
- 6%
Clinicaland
and
Translational
Investigation
Clinical
Translational
Investigation
- 71% - 71%
- 8%
Laboratory
Research
Training
Laboratory
Research
andand
Training
- 25%- 25%
Designated
Grants
- 4%
Designated
Grants
- 4%
CANCER RESEARCH INSTITUTE | 21
CANCER RESEARCH INSTITUTE, INC.
Statements of Financial Position
June 30,
2013
2012
ASSETS
Cash and cash equivalents
Pledges receivable
Bequests and other trusts receivable
Other receivables
Prepaid expenses
Investments
Office equipment and leadhold improvements, net
$
9,328,472
8,610,021
2,770,010
62,525
223,476
37,466,925
312,292
$
8,349,665
4,820,308
1,684,879
221,016
250,475
35,393,401
317,937
$
58,773,721
$
51,037,681
$
321,180
165,813
30,210,081
255,508
18,400
$
176,739
166,703
25,870,886
284,715
LIABILITIES
Accounts payable and accrued expenses
Annuities payable
Grants and fellowships payable
Deferred rent
Refundable deposit
30,970,982
26,499,043
13,782,218
2,624,026
11,633,289
2,376,322
16,406,244
14,009,611
7,901,104
3,495,391
7,221,477
3,307,550
27,802,739
24,538,638
NET ASSETS
Unrestricted:
Undesignated, available for operations
Board-designated as endowment
Total unrestricted
Temporarily restricted
Permanently restricted
$
58,773,721
$
51,037,681
2013 FINANCIAL SUMMARY (continued)
CANCER RESEARCH INSTITUTE, INC.
Statements of Financial Activities
June 30,
2013
2012
Operating support and revenues:
Public support:
General, trustee, and related
Combined federal campaigns
Bequests/memorials
Lloyd J. Old Endowed Fellowship Fund
Special events (net of direct benefit to donors of
$274,214 in 2013 and $259,387 in 2012)
Designated contributions (including in-kind
contributions of services of $609,257 in
2013 and $631,598 in 2012)
Total public support
Operating revenues:
Rental loss (net of related expenses of
$150,807 in 2013 and $174,372 in 2012)
Investment income allocation
Miscellaneous
Total operating revenues
Total operating support and revenues
$
2,489,267
536,041
2,374,246
153,630
$
3,292,021
743,783
1,976,364
1,470,761
1,844,872
1,571,370
11,345,471
18,743,527
6,869,745
15,924,044
(111,644)
1,674,479
28,954
1,591,789
(160,411)
1,646,639
3,347
1,489,575
20,335,316
17,413,619
3,385,513
12,820,580
16,206,093
3,297,450
10,843,567
14,141,017
1,098,932
1,575,557
2,674,489
985,653
1,456,586
2,442,239
18,880,582
16,583,256
1,454,734
830,363
Operating expenses:
Program services:
Science, medical and research information and
communications
Research
Total program services
Supporting services:
Administration
Marketing and development
Total supporing services
Total expenses
Change from operating activities
Non-operating activities:
Net investment gains in excess of
investment allocation
Change in value of perpetual trust
1,775,156
34,211
(2,119,362)
(28,887)
Net assets - beginning of year
3,264,101
24,538,638
(1,317,886)
25,856,524
Net assets - end of year
27,802,739
24,538,638
Change in net assets
CANCER RESEARCH INSTITUTE | 23
2013 HONOR ROLL OF DONORS
The Cancer Research Institute’s ability to advance important science and facilitate the development of immunotherapies
is made possible through the generous support of our donors—foundations, corporations, and individuals. We acknowledge
them here in gratitude for their commitment to our mission and trust in our work.
Acknowledgments listed here reflect contributions to CRI made between July 1, 2012, and June 30, 2013.
$1,000,000+
Anna-Maria and Stephen Kellen
Foundation
MedImmune, Inc.
Estate of Robert T. Ridley
The Thompson Family Foundation
$500K – $999K
Mr. and Mrs. Brian Riano
$100K – $499K
Concern Foundation
Mr. and Mrs. Maurice J. Cunniffe
Leslie and Bob Dahl
Oliver S. and Jennie R. Donaldson
Charitable Trust
Genentech, Inc.
Estate of Victor E. Hansen
The Hertz Corporation
F.M. Kirby Foundation, Inc.
John Malowany Trust
The Ambrose Monell Foundation
Estate of Jean Marie Newcomer
Julian H. Robertson Jr.
Shelter Hill Foundation
Betsy and Paul Shiverick
The Frederick William Woodworth
Charitable Remainder Unitrust
The Woodworth Family Trust
$50K – $99K
Anonymous (1)
Achelis Foundation
Robert Arnow
Mr. and Mrs. Edgar R. Berner
Estate of Ruth E. Bodbyl
Jennifer L. Brorsen and
Richard M. DeMartini
F. Hoffman-La Roche Ltd.
The John and Christine Fitzgibbons
Foundation
Georgia and Don Gogel
Oliver R. Grace Jr.
Oliver R. Grace Charitable Foundation
Marion Esser Kaufmann Foundation
Mr. and Mrs. Alexander P. Lynch
MacHeist
Orinoco Trust
Mr. and Mrs. Andrew M. Paul
The Linda C. Pinkus Fund of the
Community Foundation of
New Jersey
Lief D. Rosenblatt
Jeanne and Herb Siegel
Sharzad and Michael Targoff
Diane and Tom Tuft
Ueberroth Family Foundation
The Wildflower Foundation
$25K – $49K
The Jeanne E. and Jacob A. Barkey
Memorial Fund
Franci J. Blassberg and Joseph L.
Rice III
Bloomberg
Ann and Geoffrey O. Coley
Davis Polk & Wardwell
Debevoise & Plimpton LLP
Albert Nathan Eisenberg Charitable
Foundation Trust
Mr. and Mrs. Victor F. Ganzi
Goldman, Sachs & Co.
Herman B. Golub Charitable Trust
Joyce Green Family Foundation
Hagedorn Fund
Marlene Hess and James Zirin
Estate of Nurine C. Hoke
Mr. and Mrs. Kenneth G. Langone
Mr. and Mrs. Ronald Lauder
Thomas G. and Andrea Mendell
Mr. and Mrs. Jacques C. Nordeman
Perri Peltz and Eric Ruttenberg
Pictet & Cie
The Frank V. Sica & Colleen
McMahon Foundation
Estate of Mary and James Suthard
Estate of George C. Thomas Jr.
Turner Broadcasting System, Inc.
Lauren and John Veronis
$10K – $24K
Anonymous (1)
Abbvie Inc.
Agenus Inc.
Dr. Eva Andersson-Dubin and
Mr. Glenn Dubin
Mr. and Mrs. Rand V. Araskog
AT&T
Mary R. Baque Trust
Bristol-Myers Squibb Company
Estate of Anne Luise Buerger
C.R. Bard, Inc.
Pat and Gil Caffray
James M. Citrin
Joseph M. Cohen
Mr. and Mrs. Timothy Collins
Jennet Conant and Steven Kroft
Frederic R. Coudert Foundation
Dancing Tides Foundation Inc.
Dendreon Corporation
Mr. and Mrs. Glenn J. DeSimone
Thea Duell and Peter Cook
Patrick Durkin
Mr. and Mrs. John Eckerson
Eli Lilly and Company
Alixandra G. Englund
Mr. and Mrs. Carlos A. Ferrer
GMG Products, LLC
Gold Family Fund
John G. & Jean R. Gosnell
Foundation, Inc.
Green Charitable Foundation, Inc.
Greenhill & Co., Inc.
Shirley and Burt Harris Family
Foundation
The Hurlbert Family Foundation
Estate of Mary L. Hutchins
IMS Health Inc.
Helen L. Kay Charitable Trust
Heidi and Michael Kluger
Polo Ralph Lauren Foundation
The Florence & Edgar Leslie
Charitable Trust
James F. McCann
Merck KGaA
Emil and Toby Meshberg Family
Foundation Inc.
Donald L. Morton, M.D.
Royce E. Oliver Jr.
Paul and Anna Oschwald Trust
Mr. and Mrs. Terry O’Toole
Mr. and Mrs. Andrew M. Paul
Mr. and Mrs. Lawrence A. Rand
Red Crane Foundation
Elaine Rees
Regeneron Pharmaceuticals, Inc.
Estate of Florence V. Richardson
Adeline Ringeisen TUA
Mrs. Edmond J. Safra
Adolph and Ruth Schnurmacher
Foundation
Estate of Virginia Schuettpelz
Edith M. Schweckendieck Trust
Seaman Family Foundation
Jane and James Stern
Walter & Louise Sutcliffe
Foundation
Julie Trent
Mr. and Mrs. Andrew K. Tsai
Estate of Zelda Uthe
Wachtell, Lipton, Rosen & Katz
Estate of Lea Ward
Mr. and Mrs. Ronald G. Weiner,
Perelson Weiner, LLP
Whiting Foundation
Mr. and Mrs. Christian Zugel
$5K – $9K
Anonymous (3 donors)
Marilyn Alfeld
James Angel
Apeiron Biologics AG
Joanne Benedict
Curtis G. Bergan
BN Immunotherapeutics
Cynthia Clift and David Wassong
2013 HONOR ROLL OF DONORS (continued)
Steve Cohen
Compugen Ltd.
Corning Incorporated
Mr. and Mrs. Scott Corsair
Zoe Cruz
CT Atlantic Ltd.
Danem Foundation
Mr. and Mrs. Brennan Diaz
EisnerAmper LLP
Mr. and Mrs. Sean P. Fahey
Charles Fenster
Mr. and Mrs. Norman Freedman
Ambassador Charles A. Gargano
Gleacher & Company
Laura & Peter Grauer Foundation
A.L. Hall Trust
Immatics Biotechnologies GmbH
Immudex
Innovate International Intelligence
& Integration, LLC
Mr. and Mrs. Jim Johnson
Mr. and Mrs. George Kaufman
Megan V. Kearney
Joel Klein
Rachel Rutherford Englund
Knapp
Mr. and Mrs. Joseph M. Kopec
Mr. and Mrs. Philipe Laffont
Mr. Leonard Lauder
Mr. and Mrs. Francis L’Esperance
The Lind Partners
Mr. and Mrs. Patrick J. McGrath
Joseph and Marion L. Mitola
Family Fund
Estate of Barbara Lynne Nelson
OncoTherapy Science, Inc.
Floyd Pace and Lily Pace Trust
Estate of Eleanor Patterson
Michael Perkins
Jane and Robert Perkinson
Vickie Y. Pitzer
Mr. and Mrs. James A. Randel
Carlos Rodriguez-Pastor
The Edward John and Patricia
Rosenwald Foundation
Jeffrey H. Salzman
Carol Sawdye and John Morisano
Paul J. Sekhri
Michael Charles Sharp
Eric P. Sheinberg Foundation
Shionogi & Co., Ltd.
Mr. and Mrs. Ernest B. Smith
Mr. and Mrs. Robert M. Stavis
Mr. and Mrs. Leonard N. Stern
Tishman Speyer
Transgene
Viracor-IBT Laboratories
Roger Wilkie
Edward N. Ziegler and Gladys P.
Ziegler Private Foundation
$1,000 – $4,999
Anonymous (23 donors)
Mr. and Mrs. William Acquavella
Activartis Biotech GmbH
Mr. and Mrs. Rudolph R. Adamiak
AgonOx
Saad Ali
Jane B. Allen
Audrie and Todd Alsdorf
Amy Alspach
Donald W. Ammerman
Mr. and Mrs. Michael Anania
Mr. and Mrs. Dale P. Anderson
Mr. and Mrs. Kim C. Anderson
Robert G. Andrews
Apple
Ann M. Bailey
Matthew Banal
Bank of America Foundation
Cody Barrington
The Barrington Foundation, Inc.
Brian L. Bartlett
Mr. and Mrs. Gerald Bartolomucci
Basin Holdings
BD
Ted and Robbie Beaty
Mr. and Mrs. Everett A. Bell
Mr. and Mrs. Jonathon Berezinski
Kevin Berkemeyer
Mr. and Mrs. Howard P. Berkowitz
Mr. and Mrs. Edward M. Bermas
Mr. and Mrs. and Ms. Mark Berry
Mr. and Mrs. James Bertles
Mr. and Mrs. Larry D. Billen
Cathie Black and Tom Harvey
Steve and Kelly Bloom
Jessica Blum
Mr. and Mrs. Jeffrey Bolton
Brandeis Hillel Day School
Charlotte Brenner
Mr. and Mrs. Brian J. Brille
Mr. and Mrs. Daniel Brodsky
Tory Burch
Mr. and Mrs. Tom Burman
Mr. and Mrs. Lucien D. Burnett III
Mr. and Mrs. Joseph Califano
The Campbell Family
Mr. and Mrs. Marshall E. Canaday
Michael Capps
Pamela and John Casaudoumecq
The Cayuga Foundation
Celldex Therapeutics, Inc.
Dr. Jacob M. Chacko
Lewis Cheney
Chevron
Tracy Chou
Mr. and Ms. Alex Clain-Stefanelli
Charles G. Clarke
Mr. and Mrs. Jeffrey Clyman
Terrell T. Coco
C. Payson Coleman Jr.
Mr. and Mrs. Mark Competiello
Anna and Charles Conigliaro
Foundation
Sarah Cooper-Davis
Mr. and Mrs. Richard Corey
Corporate Risk Solutions, LLC
Mr. and Mrs. James Coyle
William S. Credle
Sidney Crews
Kirk Cromer
Our annual golf outing plays on premier courses and
offers several prizes, all in support of CRI’s work.
Jody Carlson, Rosemary Ferrer, Amanda Salzman,
and Elizabeth Muhr
CANCER RESEARCH INSTITUTE | 25
Dean Curnutt
Mr. and Mrs. John R. Curtis Jr.
Dave’s Gourmet, Inc.
Mr. and Mrs. Roberto de Guardiola
Deacon Charitable Foundation
Mr. and Mrs. Thompson Dean
Deere & Company
Della Calce Private Foundation, Inc.
Mr. and Mrs. Paul Dertien
The Honorable Martin Dickman
Mr. and Mrs. John H. Dobbins
John Patrick Driscoll
James Dunne
Nancy P. Durr
Angela and Christian Ehemann
E. Joseph Evans Charitable Trust
Louise Egdorf Fescine
Filipino American United Catholics of
the East Bay
Kristen Kelly Fisher
Amanda Fox
Mr. and Mrs. Thomas Franco
Connie Frank Foundation
Neil Gallagher
Mr. and Mrs. Robert C. Galvin
Mr. and Mrs. David Ganek
Manjit Gardner
Linda Gase
Judy and Tony Geraci
Mr. and Ms. Daniel Gerst
Mr. and Mrs. Jeffrey R. Gibbons
Charles Gibson
Kenneth A. Gill
Laurie and Jeffrey Goldberger
Mr. and Mrs. Adam Goodman
Google
Mr. and Mrs. Ronald B. Gordon
Gorjana & Griffin, Inc.
Mr. and Mrs. Vlad Gotlib
Grand Council of Royal and Select
Masters of Florida
Green Mountain Coffee Roasters, Inc.
Gretna Presbyterian Church
Isaac Guerrero
Mr. and Mrs. Lee Hanger
Castle Harlan, Inc.
Neita Harrigan
J. Ira and Nicki Harris Family
Foundation
Mr. and Mrs. William B. Harrison
Harvard Medical School, Division of
Immunology
Dr. William A. Haseltine
Mr. and Mrs. Michael Haus
Head Family Trust
Mr. and Mrs. Don Healy
Donald B. Hebb Jr.
The Joan C. & David L. Henle
Foundation
Diana Hetzel
Shawn and Heather Hickey, Christian
Rothe, Bert Horton
Himoinsa Power Systems, Inc.
Deborah A. Hodes
Dr. and Mrs. Frank Hoefflin
Mr. and Ms. Paul Hoehne
Mr. and Mrs. Burt Hoffman
Mr. and Mrs. Robert Hollenbach
Patricia Hollis
Honeywell International Charity
Matching
Thomas and Marlene Hoy Foundation
Bruce R. Huebner
Gregory Hughes
Capt. Scott Ingraham
Deborah and Arthur Jacobson
Peter Jacobson
Mr. and Mrs. Jeff Jaenicke
Mark, Stuart & Marylou Jeffs
Thomas S. and Margaret Ann Johnson
Douglas F. Johnston
Hubert Joly
Anne and Johnny Jones
Mary S. Josephs
Alecia Kampff
Karuna Foundation
Kate’s Cure
Glenn Kaun
Mr. and Mrs. James L. Kempner
Michael D. Kennedy
Mr. and Mrs. Richard Kerns
Marilyn and Robert Klett
Dasha Klyachko
Mark N. Koch
Col. Richard C. Kowalski
William Kremer
Mr. and Mrs. Kurt Krestinski
Mr. and Mrs. Jules Kroll
Mr. and Mrs. David P. Kusel
Kustoms For A Cure
Mark Kwan
Mr. and Mrs. Benjamin V. Lambert
Dr. and Mrs. Richard Landesman
Mr. and Mrs. Carey F. Lathrop
Mr. and Mrs. Matt Lauer
Mr. and Mrs. Joseph A. LeBlanc
Mr. and Ms. Gregory P. Lee
Dalia and Larry Leeds
Jeffrey T. Leeds
Morris and Lillie Leibowitz Charitable
Trust
Dr. and Mrs. Philip R. Lesorgen
Allan and Karen Levine Fund
Dr. and Ms. Richard U. Levine
Pete J. Levitas
Mr. and Mrs. Irvin L. Levy
Mr. and Mrs. Laurence R. Levy
Mr. and Mrs. Scott Lindsay
Sara M. Linfante
Local Initiatives Support Corp.
Mr. and Mrs. Donald Lundholm
LaTonya Lyles
Dr. Thomas Mack
Laurence and Tony Magro
Chris & Melody Malachowsky Family
Foundation
Mr. and Mrs. Jay Mandelbaum
Uri Mandelbaum
Redge and Carole Martin
Jane Martin and Stuart Katz
The CRI Young Philanthropists Council hosts annual
events to raise funds to support a postdoctoral
fellow.
Alexis Feldman, Sean Kiely, and Samantha Knapik
Emily Slater, Rachel Unger, Marissa Kaplan, and
Tara Michaels
Josefine Bäckström, Katharine Hovey, Christina
Brown, and Alexis Hovey
2013 HONOR ROLL OF DONORS (continued)
Mr. and Mrs. Allen Mass
Dr. Philip Mastman
Mr. and Ms. David Mayman
Lynn G. McAtee
Robert M. McKeon
W. Patrick McMullan III
Dr. and Mrs. Jeremy McVay
Nelson Mead Fund
Paul Meggs
Melcar Ltd.
Mr. and Mrs. Martin Melson
Trygve Mikkelsen
Peter Miles
Dr. Stephen Monroe
Karen Moody
Eric Moomey
Dr. and Mrs. Malcolm Moore
Mr. and Mrs. Paul D. Moran
Dr. and Mrs. Robert Moskowitz
Charlotte Moss and Barry Friedberg
Dr. Alfred Muller
Mr. and Mrs. John A. Nagy
Tracey and Richard Nanula
Jenks Necker Charitable Fund
Sergei Nedospasov, Ph.D., D.Sc.
Lynn Nesbit
Sebastian V. Nicastro
Mr. and Mrs. Robert B. Nolan
Deborah Norville and Karl G. Wellner
Mr. and Mrs. Jeffrey A. Nusbaum
Winifred K. Nyce
Leeann Ogles
Mr. and Mrs. Delbert J. Ohara
Ohio Lending Consultants LLC
James A. Olson
OMD USA, LLC
Mr. and Mrs. John Orlando
Ottilie Fund
Daniel Oxyer
Mr. and Mrs. Kenneth Palumbo
Mr. and Mrs. Sean Park
Parkell, Inc.
James and Ann Parker
Partners Capital Investment Group, LLC
Mr. and Mrs. Chetan Patil
Mr. and Mrs. Jeffrey M. Peek
Mr. and Mrs. Frank H. Penski
John Perry
Mr. and Mrs. Theodore Peyton
Kevin Pfau
Jonathan Pierson
Jennifer and Bruce Polnicky
Mr. and Mrs. John C. Ponticello
Meredith Poster and David Bukzin
Robertus Pragoji
Samuel W. Puré and M. Alison Friel
QMT Associates, Inc.
Qualcomm
Mr. and Mrs. Daniel J. Quinn
Tami Rable
Walter and Renate Rados
Grace Rapinchuk
Sanjay Rattan
Terrie L. Ray
Hulda and Michael Refermat
Douglas Reichardt
Capt. and Mrs. Brian Retherford
Mr. and Mrs. Jonas J. Rieter
Mr. and Mrs. David Riparbelli
Mr. and Mrs. Herald L. Ritch
Jason Roberts
Mr. and Mrs. Thomas E. Rothman
Robert Rushton
Rust Family Foundation
Stanley Saltzman
Mr. and Mrs. Joseph Samuels
Cathleen Schlader
Karen and Henry Schneider
Henry C. Schulte and Virgina M.
Schulte Foundation
Mr. and Mrs. Anthony J. Scotto
James M. Scrivanich
Charles D. Sears
Estate of Dorothy Sefcovic
Usha Seth
Drs. Abhinav Seth
Suril Shah
Christopher Shank
Rocky J. Sherer
Blythe Sheryl
Mr. and Mrs. Ronald C. Shortridge
Mr. and Mrs. David T. Siegel
Lois V. Smigel
Mr. and Mrs. Gordon H. Smith
Mr. and Mrs. Harrison Smith
Mr. and Mrs. Jeffrey Q. Smith
Linda K. Smith
Mary F. Smith Family Foundation
Nancy Soiefer
Stainman Family Foundation
Richard Staley
Stamford Hospital
The Honorable and Mrs. Kenneth
W. Starr
Ross L. Stevens
Dennis Stovall
Mr. and Mrs. Kok Chor Tan
Mr. and Mrs. Alfred Taubman
Jean and Kenneth Telljohann
ThomasARTS
Carole A. Thompson
Mary Thompson
Mr. and Mrs. Andrew H. Tisch
Mr. and Mrs. John Trousdale
Utility Contracting Co.
Mr. and Mrs. Jeffrey K. Valentine Sr.
Van Allen Family Foundation
Mr. and Mrs. Cyrus Vance
Sharon and Cole Varvel
Viking Global Investors, LP
Robert B. Walker
Mr. and Mrs. Webster U. Walker Jr.
Barbara Walters
Stephen Warren
Mr. and Mrs. Thomas J. Welling
Robert P. West Living Trust
Julia W. Whitaker
Gerald I. White
Jytte Winslow
Michael Woinsky
Wolfensohn Family Foundation
Hope Woodhouse and Richard Canty
Matthew Wycliff
Mr. and Mrs. Charles Zeimet
Mr. and Mrs. Jeffrey Zucker
$500 – $999
Anonymous (10 donors)
Sindhu Abraham
Mayette Acker
Anne and Richard Adler
Jean E. Aeschliman
Francis Albert
AllianceData
American Contract Bridge League Charity
Foundation
American Family Insurance
Garth Ancier
Jenny Anthony
Jessica Archer
Ares Management, LLC
Estate of Grace Arnold
E. Nelson Asiel
Mr. and Mrs. Joseph Azara
Julie Baham
Mr. and Ms. James Baldini
Mr. and Mrs. Dominic Basile
Thomas I. Batchelder
Earle S. Bates
Mr. and Mrs. Neil Bayer
Mr. and Mrs. Gerald Becker
Mr. and Mrs. John Bell
Dr. and Mrs. John L. Bennett
William Bennett
Dr. and Mrs. Alex Bernhardt
Mr. and Mrs. Alex Binderow
Mr. and Mrs. Eric Blum
Verne L. Bowers
Kerry Boylan
Brian M. Brewer
Mr. and Mrs. William K. Brewer
Mr. and Mrs. Spencer Brown
Ivan Brusic
Ramon and Terri Buckley
Jerry Budd
Dr. Marcia B. Bull
Mr. and Mrs. Albert Burnette Jr.
Alexander Burnside
Jeffrey Calvello
Rohn Campbell
Mr. and Mrs. Liborio Campo
Arturo Cecena
Mr. and Mrs. Chris Cesar
Melvin and Sandra Christ
Gilmore Chung
Laura Clark-Moore
Mr. and Mrs. Scott Clayton
Mr. and Mrs. Mervyn Clevenger
Jason Cohen
Jacki and Robert Colburn
Mr. and Mrs. Bradley L. Coley Jr.
Charles Collier
Mr. and Mrs. John Connors
Corbis Corporation
Mr. and Mrs. Ronald Couture
Clark Crawford
Mr. and Mrs. Stephen M. Cuomo
CANCER RESEARCH INSTITUTE | 27
Evelyn Cusack
Dr. Emmy Lu Cutler
Sean Dague
Kelly Daley
Mr. and Mrs. Barrie Damson
Jennifer J. Dangelo
Angel A. Davenport
Dr. Mark M. Davis
Mr. and Mrs. Marc DeBonis
Brent Deines
Mr. and Mrs. Rutger deQuay
Mili Desai
Ralph Destino
Marc Andre Dorel
Landon Doyle
Mr. and Mrs. Greg Egleston
Stacy A. Eichenlaub
EnergyIQ
Richard A. Enz
F and MWL Enterprises Inc.
Mr. and Mrs. Thomas E. Falgout
Alexis Feldman
The Milton and Sylvia Feldman
Foundation
Dr. Anna C. Ferrari
Paul and Debbie Feuerborn
John A. Flood
Mr. and Mrs. Zach Francis
Frenzel Foundation
Zoe Fried
Andrew Friedwald
Wayne Gehrt
Tim Gill
Linda Gleckler
Michael Golden
Scott Goldman
Casey Gordon
R. Raymond Gorospe
Connie Green Larry
Barbie Guerrero
Mr. and Mrs. John Hamlet
Mr. and Mrs. William Hampson
Mr. and Mrs. Robert Hanscom
Mr. and Mrs. Steven K. Harris
Mr. and Mrs. David Harrison
Robert J. Hastings
Lisa R. Heffner
Mr. and Mrs. Lawrence Heller
Mr. and Mrs. David L. Henle
Mr. and Mrs. Harvey Hennes
Michael J. Herbst
John A. Herrmann Jr.
Dr. John Holt
Dr. and Mrs. Alan Houghton
Ruth E. Hubbard
Sarah Hudson
Laurie A. Hughes
Holly J. Hutchinson
Illinois Tool Works Foundation
Ironman Arizona
Stephen H. Israel
Dr. and Mrs. Theodore J. Jacobs
Mr. and Mrs. Sidney S. Jacobson
Mr. and Mrs. Charles Jade
The Jaffe Family Foundation
CRI’s first Cancer Immunotherapy Awareness Month™, which increased public awareness about the potential
of immunotherapy to treat all different types of cancer through a number of educational activities, helped
raise more than $35,000 to support its programs. CRI staff and members of the Ludwig Collaborative and
Swim Across America lab at Memorial Sloan-Kettering Cancer Center in Times Square (top), Agenus (middle),
and Basintek (bottom), among many others, joined in wearing white on June 7, 2013.
2013 HONOR ROLL OF DONORS (continued)
Johnson & Johnson
Cynthia Lynn Jones
Matthew M. Jones
Rev. and Mrs. Patrick Jones
Dr. Victor Jongeneel
David Kane
Henry Kass
Dr. Michael Kazim
Admiral Eric Keatley
Philip Kent
Mr. and Mrs. Nick Kepler
Mr. and Mrs. Jeffrey S. Kochel
Eileen Kramer
Sriram Krishnan
Mr. and Mrs. Wayne R. Kubick
Benjamin Kuipers
Mr. and Mrs. Kevin Kuntz
Perry A. Kupietz
Dr. Phillip Lam
Mark Larrimore
Julia J. Larson
Mr. and Mrs. Marvin E. Lesser
Mr. and Mrs. Arthur Levitt Jr.
Malcolm Levy
David Lindsay
Dr. Clayton Looney
Daniel Loss
Richard Loughman
Loveall Family Fund
Mr. and Mrs. Christopher Lujan
Josefina and Gregory Lyons
Jean F. MacDonald
Kylie K. MacKinnon
Emily R. Marcus
Martins Construction Corporation
Jamie Mason and Paul Stagg
Michael Matejek
Ann F. Mather
Binu K. Mathew
Roy ‘Rem’ Mayes
Mr. and Mrs. Patrick McCloskey
John McKernan
Shaleen Mclaughlin
Derek McTyier
Susan Melson
Andrew C. Merrill
Dana Meyer
MHRC, LLC
Microsoft
Angela and Ryan Miller
Janice Miller
Geoff Minsky
Jacquelyn Mitchell
Mr. and Mrs. Craig Morgenroth
Mr. and Mrs. Paul Morken
Motorola
Mr. and Mrs. Michael E. Mozina
MRJ Trust
Uday R. Naik
Mr. and Mrs. Daniel M. Neidich
NewVac LLC
John Nowak
Michael O’Brien
Dr. Jerome Odom
Christine Ogata
Robert A. Olson
The Om Center for Yoga & Massage
Mr. and Mrs. Timothy O’Neill
Suzanne and Alex Orb
Charitable Fund
Meghan Orlandi
The Outpost Club
Vernon L. Pankonin
Rick H. Para
Mr. and Mrs. Mehmet Pasa
Barbara Pasciucco
Jaynish Patel
Claire M. Phillips
Mr. and Mrs. Randy Pitchford
Mr. and Mrs. Edward Rabin
Kristin Reid
Cathy L. Reinert
Robert P. Rittereiser
Mr. and Mrs. Bradley Robson
Sarah Robson
Barbara Rockow
Daniele Rottkamp
Mr. and Mrs. John M. Rowe
Mr. and Mrs. Mony Rueven
Ahmed Sabet
Mr. and Mrs. Patrick St. Romain
Mr. and Mrs. Geronimo J. Sanchez
Mark Schlau
Davene A. Schuh
Sarah Schultz
Marilyn Schwartz
Jane Scriptunas
Mr. and Mrs. Carl Semmelhaack
Walter D. Seward
Rebecca Sharpe and Peter Bruck
Michael Shelby
Mr. and Mrs. Paul M. Sherer
Jeffrey R. Sherman
Alison Shore
Mr. and Mrs. Richard T. Short
Dr. and Mrs. James Sieper
SignMeUp.com
Roderick Silton
Mr. and Mrs. Brian D. Silverman
Mr. and Mrs. Paul Simon
Mr. and Mrs. Vincent L. Simpson
Dan Sindel
Edward and Rorie Skei
John R. Slosar
Ellen and James Smith
John T. Smith
Shirley C. Smith Charitable Foundation
David Snow
Greg Soter
Pamela Spatz
Spencer Stuart
David Star
State Metal Industries, Inc.
Mr. and Mrs. Richard Steinberg
Dr. and Mrs. Rishon Stember
Eric Stiff
Uros Stosic
John Strang
Michelle Streit
Samantha Styles
Rajesh Subramanian
Mr. and Mrs. Joseph Sweedler
Leif R. Syversen
Joe Teja
Tennis League Network, LLC
Felicia Terry
Mr. and Mrs. Ronald A. Thalmann
The Thompson Family
Dennis Tinsley
Jennifer Trainor
Mr. and Mrs. James Trant
Jeff Travisano
Mr. and Mrs. Joseph Travisano
Mr. and Mrs. J. Fred Triggs
Trofholz Technologies, Inc.
Jane M. Twomey
Ashley A. Tyson
Mr. and Mrs. Howard R. Udell
Reginald Venable
Mr. and Mrs. Otto J. Vitale
VMware Foundation
Carrie L. Walworth
Madison L. Watkin
Mr. and Mrs. Robert M. Wepfer
Kent Werth
Brian P. Whipple
Mr. and Mrs. Gordon J. White
Williams
Dr. Carmen Wilson
Mr. and Mrs. Ronald G. Woll
Terence Woolf
Dr. and Mrs. Jerry D. Wright
Dorothy Wrigley
Mr. and Mrs. Thomas M. Yamin
Jane Zimmy and Ronald M. Neumann
ZogSports “Play For Your Cause”
Mr. and Mrs. Paul Zolenge
$250 – $499
Anonymous (9 donors)
Mr. and Mrs. John Adamiak
Adobe Systems Incorporated
Judith F. Aduddell
Aetna Foundation, Inc.
Raymond L. Ahrndt
AIG
Louis T. Alesi
Mr. and Mrs. Louis Alfero
Becky Allen
Mr. and Mrs. Lawrence M. Alleva
Mr. and Mrs. Ryan Ambrifia
American Saturated Felt
Joyce J. Andersen
Christy Anderson
Michael Angerthal
Todd Arden
Mr. and Mrs. Steven S. Ausnit
Auto-Owners Insurance Company
Robert Bach
Brendan Baker
Leila Balali
Michele I. Bank
Mr. and Mrs. Joseph Bank
Mr. and Mrs. Wayne Banks
Mr. and Mrs. Robert O. Baratta
Keith Bartell
Mary L. Bartlett
CANCER RESEARCH INSTITUTE | 29
Barbara Walters, Tony Bennett, and former New York City Mayor Michael Bloomberg at CRI’s Through the
Kitchen event at The Four Seasons Restaurant in New York City on April 21, 2013.
Ercan Bas
Rosemarie Bassi
Mehul Bastawala
Ellen Baum
The Sally Beatty and Robert Sawyer
Charitable Foundation
Mr. and Mrs. Joel Beck
Mr. and Mrs. James Becker
Mr. and Mrs. Ronald R. Becker
Brandon Bejarano
Deborah Belcher
Carl Benoit
Mr. and Mrs. Garry Bergman
The Berkowitz Family Foundation
Aaron J. Besen
Cheryl Besterman
Mr. and Mrs. Robert Bierer
Dr. and Mrs. Kent Bindl
Mr. and Mrs. James Black
S.R. Blackman
Robert Blasucci
Audrey Block
Mr. and Mrs. Anthony Boccanfuso
Joshua Boger
Mr. and Mrs. George Bouse
Mr. and Mrs. Michael J. Boyd
Ruel L. Bradley Jr.
Mr. and Mrs. Geoffrey S. Bradshaw-Mack
Harry N. Bragg
Mr. and Mrs. Bob Briggs
Deborah Keller Brown
Keith W. Brown
Dr. Paul Bryant
Michael Burka
Leslie Byelas
Andrew Callaway
Mario Calvo-Platero
Michael Campanile
Rev. Dr. Eileen Campbell-Reed
Mr. and Mrs. Darren Campili
The Can Man
Mr. and Mrs. Kevin Carey
Marie C. Carlson
Mr. and Mrs. Norman R. Cash
Mr. and Mrs. Joe Castro
Annette Chai
Mr. and Mrs. Kevin Ray Channell
Andy Chen
Mr. and Mrs. Clifton Chilcoat
Dr. Joonun Choi
Aswini Chowdappa
Karyn Christiansen
Bruce Churchill
Chad Clark, M.D.
Cohen Feeley Charitable Foundation
Dr. and Mrs. Bobby Collins
Mr. and Mrs. John Confer
Mary Jo Conklin
Mr. and Mrs. Michael R. Conklin
Hadley Cooper
Rev. and Rev. Thomas S. Cory
Chris Covington
Kevin Cox
Dr. and Mrs. Neil Crellin
Mr. and Mrs. Roy Santa Croce
Mr. and Mrs. Jack Cummings
2013 HONOR ROLL OF DONORS (continued)
Thomas D. Cunningham Jr.
Mr. and Mrs. Ted Curreri
Lynn Cutter
Irving Cypen Family Philanthropic Fund
William Dagan
Judith R. Dalgin
Mr. and Mrs. Rodger D. Daniels
David & Gilbert LLP
Patricia Delgado
Dr. and Mrs. Robert Dempsey
Mr. and Mrs. David Diamond
Mr. and Mrs. John A. DiBattista
Sharon Dietrich
Mr. and Mrs. Elliott Dilling
Mr. and Mrs. Robert Dilsheimer
DIRECTV
Elizabeth A. Dolezal
Mr. and Mrs. David L. Dorenfeld
Dr. Melissa C. Downing
Mr. and Mrs. Arthur V. Doyle
Susan Dunlap
Sandra Dalvit Dunn
Ruth Ebel
Leslie F. Ebert
Cole Eckhardt
Edison Township Ice Hockey Parents
Association
Mr. and Mrs. Daniel J. Ehrlich
Mr. and Mrs. Alan G. Ellis
Mr. and Mrs. W. J. Emerson
Mr. and Mrs. John Espy
Michael Faccioli
Francis J. Farrelly Jr.
Dana Feldman
Mr. and Mrs. Keith Fernandes
Patrick Ferrara
Carol J. Finney
Heather Fischer
Alan W. Forrest
Joele Frank
Mr. and Mrs. George From
Frozen Editorial Team
Vanessa Gaby
Stephen Gaddy
Mark Gallogly
Dr. Lisa Garrard
Mr. and Mrs. N. Pierre Gaston
Mr. and Mrs. Brian Gavin
Mr. and Mrs. Todd P. Geismann
Jane Gelfand
Lydia V. Gerard
Mr. and Mrs. Daniel Gerding
Mr. and Mrs. Vishal Ghiya
Tamer Ghoneim
Mr. and Mrs. Umberto F. Gianola
Gwendolyn M. Gibson
Heather Gilbert
Mr. and Mrs. Barry Ginsburg
Matt Given
Gregory Givens
Deidra Gold
Mr. and Mrs. Laurence Goldfein
Mr. and Mrs. Harold Goldman
Scott Goldstein
Henry Goodman
Michael Goodman
Mike Goss
Joseph Graf
Paul E. Gray Jr.
Helen A. Green
Susan M. Gudmundson
Mark & Estee Gurwitz
Mr. and Mrs. Adolf Haasen
Mr. and Mrs. Matthew Haies
Susan Hart
The Hartford Electric Supply
Company, Inc.
Tim Hartnett
Dr. and Mrs. Robert L. Hawkins
Mr. and Mrs. Jack Hawkins
Kathleen Haydel
Tisha Hayes
Jeff Hengst
Ben Henig
Stephen E. Herzog
Dr. Sausan Hilmi and Mr. Raul Navarrete
Mr. and Ms. Barry Hirsch
Harriet Hirschmann
Janet K. Hise
Dr. and Mrs. Jacob Hofman
Michael Hollinger
Dee Hood
Erwin Hosono
Anny Huang
Jeff Huber
Mr. and Mrs. Robert E. Hughes
Hon. and Mrs. Russell Humphrey
Sharon Hunt
Mr. and Mrs. Brent Hunter
Eric R. Hwang
Alana Imbruce
Dr. and Mrs. Richard Imbruce
Robert R. Irving
Mr. and Mrs. Marc J. Isaacs
Mr. and Mrs. Seymour Israel
Sy Israel
Mr. and Mrs. Jeffrey M. Jagid
Susan James
Linda and Morton Janklow
Mr. and Mrs. Chase Jarvis
Mr. and Mrs. Lewis O. Johnson
David Jonas
Robert H. Jones
Jeff Josephs
Judith Josephs
Julia’s Homestyle Bakery
Jeffrey P. Kadison
Mr. and Mrs. Anthony Kahn
Anne Kallfisch
Mr. and Mrs. Peter S. Kaplan
Laurence Karst
Mr. and Mrs. Mark Kavanagh
Kenneth Kelch
Kevin A. Kendall
Elizabeth Kessler
Mr. and Mrs. Stephen Kilbon
Kimmel & Kimmel, LLC
David King
Matthew Kinsella
Mr. and Mrs. Stephen A. Klausner
Anne Klein
Mr. and Mrs. Dennis Ko
Michele E. Koch
Dr. Kathryn B. Kogan
Alex Komoroske
David Kopis
John L. Krazinski
Maureen Kucinich
Jeremy Landman
Mr. and Mrs. Gregory F. Lang
Tina Laramie
Mr. and Mrs. Steven Lau
Gerald I. Lavery
Martin Lawler
Adam Leapley
Alan J. Lebow
Daipan Lee
Lee Family Fund
Faith and Maurice Lefkort
Christopher Leggetter
Judith J. Levine
Mary Lynne Levy
Arthur Lewis
LexisNexis
Sharon J. Liddy
Matthew Lindblom
Ethan Linen
Mr. and Mrs. Jerry Lis
Zhong Qiang Liu
Jean Dominique Lock Wah Hoon
Zen C. Lu
Mr. and Mrs. John S. Luckstone
Abigail Lynch
Mr. and Mrs. Ronald Lyslo
Mr. and Mrs. Michael D. Magidson
Michelle Maier
Mr. and Mrs. Jonathan C. Maldon
Kristen Malinconico
Lauren E. Mansfield
Nicholas Marchi
Dr. and Mrs. Harold Margolin
Renny A. Maslow
Melissa Matarrese and Daniel
McEnerney
Mr. and Mrs. Jari Mattila
John Mauro
Carson McBain
Mr. and Mrs. Russell McCall
Chris McCormick
Donna M. McDaniel
Sean McDonnell
Hugh McGaughy
Michael McGinn
Gail McGovern
McKesson Foundation
Mr. and Mrs. Rod McLain
Megan McLees
Brian McShane
Robert C. Meade Jr.
Mr. and Mrs. Douglas I. Melson
Sanjay Melwani
Mr. and Mrs. Rob Meyer
Arthur N. Michell
Dr. Wayne Henry Miller
Judd Milne
Carter Mitchell
Mr. and Mrs. Rajkumar Molugu
CANCER RESEARCH INSTITUTE | 31
Regis Philbin
Former New York State Governor George Pataki,
Lauren Veronis, and Charles Gargano
Brenda E. Moore
Mr. and Mrs. John R. Morris
MWI Veterinary Supply
Alan Myers
Stuart Neal
Gordon R. Nearing
John Henry Nelson Jr.
Mr. and Mrs. Timothy Nichols
Lisa Nix
Daniel Noday
Luis A. Noriega
Erin Norris
Robert Northington
Northlake Village
Northrop Grumman Corporation
Steven Noss
Karren O’Donnell
Jill O’Donnell-Tormey, Ph.D.
Mr. and Mrs. Timothy S. Oey
Siobhan O’Hare
Craig Olin
Sandra Olson
Mr. and Mrs. Vern Onstine
Mr. and Mrs. Donal J. Orr
Maxwell D. Osborne
Kate Parker
Mr. and Mrs. James E. Parrish
Dr. and Mrs. Michael Parry
Brian A. Pasquinelli
Andrew T. Patsiner
Carolyn M. Patterson
David J. Paul
Dr. Steven Pearlman
Mr. and Mrs. Scott H. Pease
Ursula Pellegrino
Mr. and Mrs. Roy T. Peraino
Dr. Jerry Perlman
Jean Peterson
The Pfizer Foundation
Mr. and Mrs. Geoffrey P. Picket
Gregory Pierce
Pinnacle Bank
Stephanie Pinney
Dr. and Mrs. Robert Plansky
Mr. and Mrs. Richard Plese
Mr. and Mrs. Fred Plotkin
Helene Polin
Douglas Pollina
Allan S. Posner
Howard and Nancy Powell
Dr. Matthew H. Power
Mr. and Mrs. George L. Poythress
Mr. and Mrs. Richard H. Pratt
Jason Preslar
Kimberly Price
Marvin Price
Mr. and Mrs. Alfred J. Prince
Principal Financial Group
Jean S. Prokopow
Promise Communispace
Steven M. Rabinowitz, Esq.
Mr. and Mrs. Gary Radziewicz
Paul Rago and David Small
Trevor Randolph
Douglas Ratto
Maxine Ray
The Red Hat Manor of Merritt Island
Mary Redman
Sheila K. Reed
Daren V. Reid
John Reid-Dodick
Eric Reimnitz
Mr. and Mrs. Dennis M. Reinert
Steve Reinstadtler
Mr. and Mrs. Roy Rhodes
Christopher Richmond
Donna L. Rinehart
Col. and Mrs. James L. Roach
Linda Robinson
John C. Rockwell
Mary Jane Rodgers
Dr. Dorothy Levin Rosenfeld and Dr. Alvin A.
Rosenfeld
Mr. and Mrs. James B. Rosenwald Jr.
Bernard Ross
Mr. and Mrs. Jonathan Roth
Mr. and Mrs. Victor Rovani Sr.
Dr. and Mrs. Guillermo J. Rozas
RSI, LLC
Darrell Rubens
The Rubicon Project
Patricia Rubin
Jessica Rudman
Patricia Sack
Mr. and Mrs. Stephen J. Saft
Mr. and Mrs. Mark Sage
St. Stephen’s Anglican Church
Lawrence E. Samelson, M.D.
Mr. and Mrs. Gregory J. Sample
Kelsie Sams
Scott Sands
Jane Sapery
Mr. and Mrs. George Sarner
Barbara Sastre
Alice J. Savic
Savitsky, Satin and Bacon
Denise Schemenauer
Mr. and Mrs. Dick Schliesmann
Mr. and Mrs. Jon Schmitz
Mr. and Mrs. Theodore Schnitzer
Mr. and Mrs. Michael E. Schultz
Alexander Seaver
MacLean Sellars
Mary Setlock
Mr. and Mrs. Anish P. Shah
Mr. and Mrs. Solly Shamoil
Karen Shapiro
Betsy H. Sharley
Susan Sheeran
Mr. and Mrs. Neal Sheladia
Barbara L. Sheldon
Mr. and Mrs. Robert Sheldon
Marti Shelton
Mr. and Mrs. Jesse Shereff
Rahul Shewakramani
Michael Shinoda
Shoreline Family Chiropractic & Wellness
Michael Sirkin
Scott Sklar
Abby G. Smith
2013 HONOR ROLL OF DONORS (continued)
Brad Smith
Cindi L. Smith-Walters
Jennifer Smith
Jody Smith
Mr. and Mrs. Scott Sokol
Mary Sorgi
Mr. and Mrs. Irwin Sperber
Elizabeth Speth
Dr. and Mrs. Charles R. Steinberg
Mr. and Mrs. Allan Stern
Mr. and Mrs. Paul Stevelman
Stewart Stockdale
Joseph E. Stockwell Jr.
Robin Strong
Terence Sullivan
Barbara J. Sutton
Mr. and Mrs. Jan Suwinski
Peggy J. Sweeney
Marc Tabah
Mr. and Mrs. Aaron Tag
Scott W. Talbert
Tampa Orlando Pinellas Jewish
Foundation Inc.
Mr. and Mrs. Kenneth P. Tegels
Elizabeth Q. TenEyck
Athalie A. Terry
Mr. and Mrs. Thomas Terwilliger
Todd K. Testerman
Mr. and Mrs. Ernest L. Thomas
Thomason Management
James L. Thompson
Mr. and Mrs. George Thompson
William Thompson
Tilcon New York, Inc
Lacey Tisch
Torch Club of Calistoga
Kenneth M. Travis
Phyllis F. Trefz
Fredrick Tucker
Mr. and Mrs. Robert Underhill
Mr. and Mrs. Adam Vengrow
Kara Ventura
Patrick Vien
Mr. and Mrs. Jim Vincent
Dianne Vorpahl
Mr. and Mrs. Mark Waite
Mr. and Mrs. Stuart Waldstreicher
Mr. and Mrs. Jeffrey B. Warner
Melani Weber
Emily Wellikoff
Mary White
Charles Wiegold
Mr. and Mrs. Laurence S. Wilken
Rebecca E. Williams
Diane Wilson
Lawson T. Winslow
Nancy J. Wolff
Barbara F. Wood
Mr. and Mrs. Richard B. Wyman
Joel M. Yesley
Dr. and Mrs. Way Yin
Mary L. Yowell
Zachys Wine and Liquor Inc.
Strauss Zelnick
Lillian Zietz
Thomas Zitiello
Through the Kitchen at The Four Seasons restaurant in New York City delights guests annually and raises
significant funds to support CRI and its Irvington Postdoctoral Fellowship Program.
1-800-FLOWERS.com CEO Jim McCann, Marybeth Mullen, and Philip Bleser
CANCER RESEARCH INSTITUTE | 33
HELEN COLEY NAUTS SOCIETY
The Helen Coley Nauts Society recognizes donors who have included the Cancer Research Institute in their estate plans. Through deferred gifts,
bequests, trusts, and other planned giving instruments, these thoughtful individuals safeguard the Institute’s financial future. The Society is
named in honor of Helen Coley Nauts, CRI’s founder, whose passionate belief that the immune system could one day be harnessed to control
cancer has helped make this powerful vision a reality today. If you would like to learn more about making a planned gift to CRI, please contact
Emily Livingstone at [email protected], or call us at 212-688-7515.
Helen Coley Nauts
Anonymous (6)
Estelle Abas
Peter Adams
Abigail Alderman
Olga Aleskas
Mildred E. Alexander
Frederick E. Allard
Edith M. Amateau
Peggy Anderson
Frances Antopol
Freda S. Armstrong
Grace Arnold
Geneva A. Arthur
Ruth Ascher
Rex and Virginia Ashdown
Lee Asher
Belle Asherman
Alice Auerbach
Jeanne Avegno
Else Baier
Olga Baker
Marion Balen
Mary R. Baque
Dorothy Barbeau
Jeanne E. and Jacob A. Barkey
Mr. and Mrs. Kenneth Barmore
William Barr
Florence and Ben Barrack
Rose Barrow
Isabella Williams Bartholow and Bruce
Burdette Bartholow
Etta Baum
Evelyn Beekman
Frank L. Bell
Germaine Benesch
William A. Berkey
Stuart Bernard
Lucille Bernot
Herta J. Bernstein
Vincent L. Bessey
Grace M. Bishop
John Bittel
Guy Bjorkman
Leslie J. Blain
Anna H. Blankstein
Paula J. Blatter
Ruth Evelyn Bodbyl
Eleanor Bodnar
Ronald J. Bogus
Lawrence H. and Nancy E. Bonander
Mary Borbeck
Rita Borenstein
Robina C. Bouchard
Anna Isabel Boyd
Hugh R. Boyd
Barbara Brown Boyer
Joy B. Breidling
Lucille Brents
A. Arthur Bressman
Brian M. Brewer
Victor E. Broll
Albert N. Brooks
Minnie E. Brown
Virginia Bruner
Alfred R. Brunner
Estate of Anne Luise Buerger
Lucille A. Buland
Mary C. Bundy
Robert W. Burns and Lois M. Burns
Dale T. Butterwick
Joy Biggs Buttle
Tracy Campbell
Angelina Carbone
Alfred Carlucci
Julia Carlucci
Pandora Rudland Carroll
Donald O. Carswell
Melba Case
Mary Elizabeth Catto
Doris M. Clanin
William James Clapp
William H. Coffee
Bernice Cohn
Gwendolyn Colburn
Mr. and Mrs. Raymond Cole
Edythe E. Coleman
Bradley L. Coley, Jr.
Louis Comedy
Phyllis L. Conley
Vivian E. Conner and Ross I. Conner
Lottie M. and Charles H. Cook
Salvatore Corsaro
Audrey Cowan
Eleanor H. Cromley
Elmira Crosby
Julia B. and John R. Curtis
Vincent D’Amico
Annabelle L. Danzig
Carleen Davis
Alice Dawes
Aileen Adele De Long
Eustis Dearborn
Emma Deters
Betty Disbrow
Adelaide J. Dodge
Sandford Dody
Mary Ann Draus
Blanche Elizabeth Eckerts
Rita Eggert
Dorothy M. Eiser
Earl R. Elliott
Pauline E. Elliott
Ruth Engelberg
Valera L. Ennis
Helen Epstein
Nathan Epstein
Max G. Eriksen
Ned A. and Florence L. Etkin
Juanita M. Evans
Mary S. Fadeley
Helen Jean Falk
Herbert Lynn Fann
Barbara Feldman
Carlos A. Ferrer
Adelaide E. Ferris
Louise Egdorf Fescine
Elsie K. Filonchik
Frances E. and Mary H. Flood
Josephine Fonti
Florence A. Forni
Bernard W. Forrest
Carole D. Franklin
Clay Frazier
Lucille O. French
Alice M. Fried
Anne Fruhner
Lena Silverstein Fuhrman
Gay H. Gahagan
Zoltan Galdi
Eugene G. Gallant
Peter Gallant
Mollie E. Gang
Sofie Garafola
Salvador Garcia
B. I. Garlinghouse
E. Yvonne and William O. Geisert
Stella Gentile
Mildred Gentry
Penelope M. Georgiadis
Mercedes C. Gerhard
Patricia J. Getsfried
Janet M. Gifford
Regina Gilmour
Steven Ginsberg
Edna E. Glaessel
Eleanor Goldberg
Philip Goldblatt
Doris Gordon
John G. & Jean R. Gosnell
Norman Gottlieb
Dorothy M. Graham
E. Ruth Grant
Annette and Owen Gray
Bernice E. Grilleaux
Floyd Dale Grisham
Zoe S. Grove
Ronald J. Guglielmino
Marianne C. Hafner
Jeanine Hair
Nelle B. Haire
Adrian Leroy Hall
Diane Ham
Mr. and Mrs. Virgil Hamby
Frances E. Hanneman
The Hansen Trust
Loretta D. Hardy
Evelyn H. Harris
Lori Harris
Ottis C. Harris
Helaine T. Harrison
Yetta Hatch
Anne M. Hauser
James Leon Hawkins
Margaret Hayman
Donald P. Heim
Virginia Hemme
Robert J. Hendry
Fredrick Charles Henne
Senora Henry
Marion Hewett
Kay Hilton
Margot Hoffmann
Nurine Hoke
Diane and Don Holmes
Eva M. Holmes
Nellie Huff
Grace M. Humphrey
Mary L. Hutchins
Fred W. and Idell E. Iltner
Madeline Inguagiato
Ruby R. Jankiewicz
Lynn and Eldon Jasper
Warren R. Jecklin
Basil and Doreen Joffe
Ruth Harvey Johnson
Doris Kabat
Rosemary Kaplan
Sally J. Kaplan
Sara Katz
Bertha E. Kaufman
Samuel Kay
Blanche C. Kelly
Jean Kemp
Hugh W. Kennedy
Mercedes E. Kent
Elsie E. Kiel
Corinne Kiell
Theresa A. Kiely
Edward L. Kilroe and Mary B. Kilroe
Hilda Kirson
Shirlene Kisak
Marilyn and Robert Klett
Hugo and Ruth Klotz
Anne Koch
Truby Joy Kohl
Mr. and Mrs. Harry Kompanek
Fred and Juanita Koors
Harry A. Kraus
Mary T. Kraus
Naomi P. Kruse
Murray Kupferman
Hiroko Kyuba
Rose Lachow
Sidney G. LaDue
Anna Lagstein
C. Linda Lambert
Jewell Marie Lampkin
Marguerite Landis
Louise G. Lane
Caryl Lou Langford
Elizabeth S. Larkin
AnneMarie LaValle
Florence and Edgar Leslie
Polly Annenberg Levee
James F. Levens
Frances Leventritt
Betty Lou Levin
Esther Levine
Beatrice Levy
Simon Lifshatz
Patricia A. Lindner
George H. Lindskog
Roseline Lissak
Johanna Loeb
Ruby Q. Lokensgard
Peter J. Lommen
Albie A. Adams Loving
Mr. and Mrs. William H. Lyford
Gertrude A. Lynch
Hjordes Diane Lyttle
Eleanor D. MacCracken
Emilie Machalinski
Catriona Macleod
William S. Maddenborough
David Madsen
Henrietta Malbin
Herbert J. Maletz
Isabelle C. Malone
Anna Malowany
John Malowany
Ferne Magialardo
B. M. Marinko
Genevieve Martin
Louemma Martin
Lowell A. Martin
Raleigh L. Martin
Blanca Mattalia-Wyrzykowski
Mildred G. Matz
Margaret Mazzey
Michael I. McBride
Helen McCann
Cecil McClernon
Annette McDonald
J. Donald McKinney Jr.
Norma J. McPherson
Jan Mears
Grace Muriel Mecchi
Nancy Jeanne Merkel
Sidney Meskin
Ethel L. Meyer
Ezilda Michel
Helen T. Middleton
William D. Miller
Alex Mitchell
Mr. and Mrs. Charles G. Moore
Janet P. Morgan
Maza D. Morris
Louise and Peter Moseychuk
Bryant A. Muenzen
Alexander Munchweiler
Judith K. Murphy
Kathryn T. Murphy
Martin F. and Irene R. Murphy
Thomas P. Murray
Naomi Myers
Mayumi Nakagawa and John K. Lai
Rita Nasser
Alice A. Nauts
Paula M. Neal
Barbara Lynne Nelson
Rose E. Nelson
Jean Marie Newcomer
William E. Newton and Freda E. Newton
Herb H. Nichols
Bernard R. Niewoehner
Geneva W. Nolen
Jacques C. Nordeman
Mary M. Nowak
Mary Nunez
Dorothy B. Nurick
Harry A. and Margaret M. Oak
Nora Odets
Arvilla Ogden
Michele A. Ognibene
Roselyn R. Olken
Alice Orlich
Mary O’Rourke
Paul and Anna Oschwald
Albert Ottinger
Floyd Pace and Lilly E. Pace
Marjorie W. Packwood
Erma N. Panfilio
Andrew Reid Paton
Eleanor T. Patterson
Foster Clae Patton
Frederick V. Payne
Nancy Elizabeth Pease
Donald H. Peper
CANCER RESEARCH INSTITUTE | 35
HELEN COLEY NAUTS SOCIETY (continued)
Agnes Phelps
Elizabeth F. Phillips
John Piercy
Harriet-Anne Pierson
Rochelle Pinz
Dorothy Plumb
Mabel Plunkett
Nick J. Pokea
David M. Polen
Esther Posin
Richard Potruch
Despina Poulos
Joyce A. Prime
Dorothy S. Pritchard
Aspasia Radoumis
Carol Diane Ranken
James B. Ransohoff
Esther Reed
Harry Delos Reich
Helen Relkin
Floris J. Renk
LaDonna Reynolds
Florence V. Richardson
Adam J. Richter
Virginia L. Riddle
Robert T. Ridley
Adeline Ringeisen
Dr. Fred Ringel
Veronica A. Rose
Susan Rosenberg
Moises Rubiano
Dorothy and Ernest Rueppel
Gloria Ruminsky
Hedwig Salzer
Lydia B. Scannell
Martha Schneller
Virginia Schuettpelz
Helen R. Schutt
Ruth Schwartzman
Rev. Harold Bend Sedgwick
Dorothy K. Sefcovic
Clara Senk
Natalie Shebs
Dorothy M. Sheese
Margaret Sheets
Donald Sherwood
Renee and Irwin Shishko
Laura M. Sidener
Katherine U. Silva
Belle V. Silverstein
Augusta Simon
Roma Sinclair
Estelle Singer
Jean V. Sirles
Alice Jean Smith
Catherine M. Smith
Clarence Smith
Mr. and Mrs. Ernest B. Smith
Howard G. Smith
Kevin L. Smith
Patricia Smith
Ruth Sneve
Vera Marie Snider
Esther and Harold Sohmer
Fred E. Spencer
Jacqueline Spencer
Remy R. Sprouse
Brenda M. St. James
Gerald J. Steinberg
Leopold Steindecker
Anna Stephan
Robert L. Stevens
Mary Malcolm Stiles
Frieda Coons Studley
Dorothy H. Sullivan
Myrtle B. Summers
Agnes Katscher Sunley
John Supon
Mary and James Suthard
Mary Carol Talerico
Maureen Tannehill
Carl E. Thomas
George C. Thomas Jr.
Geraldine E. Thomas
Overton Arnold Thompson
Viola Mae Thompson
John R. and Anita Timmel
Carola S. Trier
Jessie C. Tripp
John D. Turkel
Zelda M. Uthe
Paul E. Van Cleve
William R. Vass
Josephine S. Villeman
Antone L. and Myrtle H. Vinelli
Anne D. Vinton
Linda Vono
Esther and Stanley Wade
Ethel Wagner
David Walker
Thomas Walsh
Julia Walz
Lea Ward
Irene M. Watkins
Dorothy Waugh
Albert L. and Ione A. Weickert
Rose C. Weisel
Leonard Weiss
Robert P. West
Anna M. Wheeler
Agnella L. Widmer
Geneva K. Widmer
Margaret Wiegandt
Saul J. Wiener
Loretta M. Wiggins
Lorna Katherine Wilkinson
Francis I. and Harriet B. Wilks
Josephine H. Williams
Ora Brown Windle
Mr. and Mrs. Norman J. Woodhams
Frederick W. Woodworth
John A. Wootton
Josephine Wootton
Nettie Wright
Ethel R. Young
Marion E. Youngberg
Gloria Zaino
Marion Zell
CENTENNIAL CIRCLE
The Centennial Circle celebrates donors
who have made a lifelong commitment to
supporting the Cancer Research Institute.
Members of this loyal group have made 75
or more gifts to CRI during their lifetime.
Anonymous (2)
Bertha Auerbach
Ellen Beloff
Mr. and Mrs. Ira M. Boskey
Lauren B. Burns
Harriet E. Charles
Mr. and Mrs. Irving Cohen
Selma Davidson
Mr. and Mrs. Stephen C. Elkin
Mr. and Mrs. Ivan S. Fischman
Anne E. Gentile
Mr. and Mrs. Gary R. Ginsberg
Mr. and Mrs. Leonard Gold
Helen A. Green
Renee A. Harris
Harvey A. Herbert
Mrs. Stephen M. Kellen
Mr. and Mrs. Elliot Leitner
Mr. and Mrs. Michael H. Levy
Charles J. Lurie
Mr. and Mrs. Charles Lyttle II
Mr. and Mrs. Arthur Nasso
Esther Ravin
Mr. and Mrs. Jonas J. Rieter
Mr. and Mrs. Milton S. Rubin
Clifford M. Rutter
Mr. and Mrs. Stanley Shuman
Mr. and Mrs. Marvin Stillman
William Tracy
Mr. and Mrs. Everett L. Wessner
Alan N. White
Florence Wisler
BOARD OF TRUSTEES
CHAIRMEN
John B. Fitzgibbons
Chairman and CEO
Basin Holdings US LLC
New York, NY
Paul C. Shiverick
Partner
Seminole Management Company, Inc.
New York, NY
VICE CHAIRMEN
Edgar R. Berner
Partner
John Lang, Inc.
New York, NY
Donald J. Gogel
Chairman and CEO
Clayton, Dubilier & Rice, LLC
New York, NY
Jacques C. Nordeman
Chairman
Nordeman Grimm, Inc.
New York, NY
TREASURER
Glenn J. DeSimone
Greenwich, CT
Patrick J. Durkin
Managing Director
Barclays Capital
New York, NY
Carlos A. Ferrer
Founder and Managing Member
Ferrer Freeman & Company, LLC
Greenwich, CT
Margot E. Freedman
Larchmont, NY
Robert C. Galvin
Principal
Galvin Consulting
Ridgefield, CT
G.S. Beckwith Gilbert
President & CEO
Field Point Capital Management Company
Greenwich, CT
Mitchell H. Gold, M.D.
Chairman
Alpine Biosciences
Seattle, WA
Geoffrey O. Coley
New York, NY
Oliver R. Grace Jr.
Palm Beach, FL
SECRETARY
Sandra Coudert Graham
Oyster Bay, NY
Thomas G. Mendell
T.G. Mendell Corp.
New York, NY
MEMBERS
Peter L. Bloom
Advisory Director
General Atlantic LLC
Greenwich, CT
James M. Citrin
Leader, CEO Practice
Spencer Stuart
Stamford, CT
Maurice J. Cunniffe
Chairman & CEO
Vista Capital Corporation
Greenwich, CT
W. Robert Dahl
Vice Chairman
WRD Capital
Darien, CT
Richard M. DeMartini
Managing Director
Crestview Partners
New York, NY
Michael M. Kellen
Co-President
Arnhold and S. Bleichroeder
Holdings, Inc.
New York, NY
Alexander P. Lynch
Partner
White Deer Energy
New York, NY
James F. McCann
CEO
1-800-FLOWERS.com
Carle Place, NY
Andrew M. Paul
Managing General Partner
Enhanced Equity Funds
New York, NY
Brian Riano
CEO and Co-Founder
Claren Road Asset Management, LLC
New York, NY
Lief D. Rosenblatt
Partner
ENE Investco Management
New York, NY
Howard B. Schiller
Executive Vice President and
Chief Financial Officer
Valeant Pharmaceuticals
International, Inc.
Bridgewater, NJ
Paul J. Sekhri
Group Executive Vice President, Global
Business Development and Chief Strategy
Officer, Teva Pharmaceutical Industries Ltd.
Petach Tikva, Israel
Frank V. Sica
Managing Partner
Tailwind Capital
New York, NY
James A. Stern
Chairman and Founder
The Cypress Group
New York, NY
Michael B. Targoff
Vice Chairman of the Board
Loral Space & Communications
New York, NY
Andrew K. Tsai
Managing Principal
Chalkstream Capital Group, L.P.
New York, NY
Diane Tuft
New York, NY
Heidi Ueberroth
Director
Pebble Beach Company
New York, NY
Lauren S. Veronis
New York, NY
Ronald G. Weiner
President
Perelson Weiner LLP
New York, NY
James A. Wiatt
CEO
CIW Consulting
Los Angeles, CA
CANCER RESEARCH INSTITUTE | 37
BOARD OF TRUSTEES
SCIENTIFIC ADVISORY COUNCIL
TRUSTEES EMERITI
DIRECTOR
Carter F. Bales
Chairman and Managing Director
NewWorld Capital Group, LLC
New York, NY
James P. Allison, Ph.D. 2,3,5,6,7
The University of Texas
MD Anderson Cancer Center
Houston, TX
Howard P. Berkowitz
New York, NY
Donald G. Calder
Chairman
Clear Harbor Asset Management
New York, NY
Stuart P. Davidson
Managing Director
Labrador Ventures
Menlo Park, CA
Bruce D. Dixon
Retired Partner
Ernst & Young
Greenwich, CT
Mrs. Charles G. Gambrell
Charlotte, NC
William O. Grabe
Advisory Director
General Atlantic LLC
Greenwich, CT
Charles M. Grace
Los Angeles, CA
Mrs. Oliver R. Grace
New York, NY
Joyce Green
Westhampton Beach, NY
Ann W. Jackson
New York, NY
Arthur L. Jacobson
Vice President, Investments
SmithBarney
Indian Wells, CA
Mrs. Stephen M. Kellen
New York, NY
Robert A. Posner
Managing Director
Commonwealth Holding, LP
Brookline, MA
Julian H. Robertson Jr.
Chairman
Tiger Management LLC
New York, NY
Winthrop H. Smith Jr.
Chairman
Summit Ventures NE, LLC
Warren, VT Lisa M. Coussens, Ph.D.
Oregon Health & Science University
Portland, OR
Peter Cresswell, Ph.D. 2,6
Yale University School of Medicine
New Haven, CT
ASSOCIATE DIRECTORS
Glenn Dranoff, M.D. 3,4,5
Dana-Farber Cancer Institute
Boston, MA
Charles G. Drake, M.D., Ph.D. 5
The Johns Hopkins School of Medicine,
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Carl F. Nathan, M.D. 2,3,6
Weill Cornell Medical College
New York, NY
Michael L. Dustin, Ph.D. 6
NYU Langone Medical Center
New York, NY
Ellen Puré, Ph.D. 6,7
University of Pennsylvania School of
Veterinary Medicine
Philadelphia, PA
Richard A. Flavell, Ph.D., FRS 2
Yale University School of Medicine
New Haven, CT
Robert D. Schreiber, Ph.D.
Washington University School of Medicine
St. Louis, MO
2,3,5,6,7
Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center and
Ludwig Cancer Research
New York, NY
4,5
MEMBERS
Frederick W. Alt, Ph.D. 2,6
Howard Hughes Medical Institute, Boston
Children’s Hospital and Harvard Medical
School
Boston, MA
Richard Axel, M.D. 1,2
Columbia University Medical Center
New York, NY
Nina Bhardwaj, M.D., Ph.D. 5,6
Tisch Cancer Institute, Icahn School of
Medicine at Mount Sinai
New York, NY
Harvey Cantor, M.D. 2
Dana-Farber Cancer Institute
Boston, MA
Jonathan S. Cebon, Ph.D., FRACP
Austin Health/Ludwig Cancer
Research
Melbourne, Australia
Vincenzo Cerundolo, M.D., Ph.D.
MRC Human Immunology Unit,
University of Oxford
Oxford, United Kingdom
4
Thomas F. Gajewski, M.D., Ph.D. 5
The University of Chicago Medicine
Chicago, IL
Laurie H. Glimcher, M.D. 2
Weill Cornell Medical College
New York, NY
Philip D. Greenberg, M.D. 3,6
University of Washington School of Medicine
and Fred Hutchinson Cancer Research
Center
Seattle, WA
Patrick Hwu, M.D.
The University of Texas
MD Anderson Cancer Center
Houston, TX
Elizabeth M. Jaffee, M.D.
The Johns Hopkins School of Medicine,
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Carl H. June, M.D. 4
Abramson Cancer Center, Perelman School
of Medicine at the University of Pennsylvania
Philadelphia, PA
Michael Karin, Ph.D. 2
University of California, San Diego
La Jolla, CA
John M. Kirkwood, M.D.
University of Pittsburgh Cancer Institute
Pittsburgh, PA
3,5
Max D. Cooper, M.D. 2
Emory University School of Medicine
Atlanta, GA
George Klein, M.D., D.Sc.
Karolinska Institute
Stockholm, Sweden
2,3
Alexander Knuth, M.D. 3,4,5
National Center for Cancer Care and
Research NCCCR, Hamad Medical
Corporation
Doha, Qatar
Lewis L. Lanier, Ph.D. 2,6
University of California, San Francisco
San Francisco, CA
Jeffrey V. Ravetch, M.D., Ph.D. 2,6
The Rockefeller University
New York, NY
Dan R. Littman, M.D., Ph.D. 2,6
New York University School of Medicine
New York, NY
Stanley R. Riddell, M.D. 5
Fred Hutchinson Cancer Research Center
Seattle, WA
Tak W. Mak, Ph.D., D.Sc., F.R.S.C. 2,6
The Campbell Family Institute for Breast
Cancer Research at Princess Margaret
Hospital, University Health Network,
University of Toronto
Toronto, Canada
Alexander Y. Rudensky, Ph.D. 2,6
Memorial Sloan-Kettering Cancer Center
New York, NY
Philippa C. Marrack, Ph.D. 2
National Jewish Health and the
University of Colorado Denver
Denver, CO
Cornelis J.M. Melief, M.D., Ph.D.
Leiden University Medical Center
Leiden, The Netherlands
Bijan Safai, M.D., D.Sc.
New York Medical College
Valhalla, NY
Shimon Sakaguchi, M.D., Ph.D.
Immunology Frontier Research
Center, Osaka University
Osaka, Japan
2,3
3
Ira Mellman, Ph.D. 2
Genentech
South San Francisco, CA
Malcolm A.S. Moore, D.Phil.
Memorial Sloan-Kettering Cancer Center
New York, NY
Donald L. Morton, M.D.
John Wayne Cancer Institute
Santa Monica, CA
Lee Nadler, M.D.
Dana-Farber Cancer Institute
Boston, MA
Kunle Odunsi, M.D., Ph.D. 4,5
Roswell Park Cancer Institute
Buffalo, NY
Drew M. Pardoll, M.D., Ph.D. 3,6
The Johns Hopkins School of Medicine, The
Sidney Kimmel Comprehensive Cancer
Center
Baltimore, MD
William E. Paul, M.D. 2
National Institute of Allergy and
Infectious Diseases, NIH
Bethesda, MD
Klaus Rajewsky, M.D. 2,3
Max-Delbrück Center for Molecular Medicine
Berlin, Germany
Anjana Rao, Ph.D. 2,6
La Jolla Institute for Allergy and
Immunology, Sanford Consortium for
Regenerative Medicine
La Jolla, CA
Lawrence E. Samelson, M.D. 6
National Cancer Institute, NIH
Bethesda, MD
Hans Schreiber, M.D., Ph.D.
The University of Chicago
Chicago, IL
3,6
Robert H. Vonderheide, M.D., D.Phil.
Abramson Cancer Center, Perelman School
of Medicine at the University of Pennsylvania
Philadelphia, PA
Hao Wu, Ph.D. 6
Boston Children’s Hospital and
Harvard Medical School
Boston, MA
Cassian Yee, M.D. 6
The University of Texas
MD Anderson Cancer Center
Houston, TX
Rolf M. Zinkernagel, M.D., Ph.D.
University of Zürich
Zürich, Switzerland
1,2,3
1 Nobel Laureate
2 Member, National Academy of Sciences
3 Member, Academy of Cancer Immunology
4 Clinical Accelerator Scientific Advisory Committee
5 CLIP Review Committee
6 Postdoctoral Fellowship Review Committee
7 STaRT Review Committee
Ton N. Schumacher, Ph.D.
The Netherlands Cancer Institute,
Amsterdam, and Leiden University, Leiden,
The Netherlands
Craig L. Slingluff Jr., M.D. 4
University of Virginia School of Medicine
Charlottesville, VA
Mark J. Smyth, Ph.D.
Queensland Institute of Medical Research
Queensland, Australia
Pramod K. Srivastava, M.D., Ph.D. 3,5
University of Connecticut Health Center
Farmington, CT
Susumu Tonegawa, Ph.D. 1,2
Massachusetts Institute of Technology
Cambridge, MA
Giorgio Trinchieri, M.D. 3,6
National Cancer Institute, NIH
Frederick, MD
Emil R. Unanue, M.D. 2
Washington University School of Medicine
St. Louis, MO
Ulrich H. von Andrian, M.D., Ph.D. 6
Harvard Medical School and Boston
Children’s Hospital, Boston; and The Ragon
Institute of Massachusetts General Hospital,
MIT, and Harvard University
Cambridge, MA
CANCER RESEARCH INSTITUTE | 39
OTHER SCIENTIFIC AND LAY LEADERSHIP
CVC TRIALS NETWORK
Director & Scientific Advisory Committee Chair
Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center
and Ludwig Cancer Research
New York, NY
Scientific Advisory Committee
Jonathan S. Cebon, Ph.D., FRACP
Austin Health/Ludwig Cancer Research
Melbourne, Australia
Glenn Dranoff, M.D.
Dana-Farber Cancer Institute
Boston, MA
Carl H. June, M.D.
Abramson Cancer Center, Perelman School
of Medicine at the University of Pennsylvania
Philadelphia, PA
Alexander Knuth, M.D.
National Center for Cancer Care and
Research
Hamad Medical Corporation
Doha, Qatar
Kunle Odunsi, M.D., Ph.D.
Roswell Park Cancer Institute
Buffalo, NY
Craig L. Slingluff Jr., M.D.
University of Virginia Cancer Center
Charlottesville, VA
Finance, Intellectual Property,
Clinical Trials Management, & Administration
Adam Kolom
Cancer Research Institute
Los Angeles, CA, and New York, NY
Jill O’Donnell-Tormey, Ph.D.
Cancer Research Institute
New York, NY
Jonathan Skipper, Ph.D.
Ludwig Cancer Research
New York, NY
Ralph Venhaus, M.D.
Ludwig Cancer Research
New York, NY
Linda Pan, Pharm.D.
Ludwig Cancer Research
New York, NY
Gerd Ritter, Ph.D.
Ludwig Cancer Research
New York, NY
Lynne A. Harmer
Cancer Research Institute
New York, NY
Global Clinician and Scientist
Membership
James P. Allison, Ph.D., The University of
Texas MD Anderson Cancer Center, USA
Maha Ayyoub, Ph.D., Centre de Lutte Contre
le Cancer Nantes-Atlantique, France
Nina Bhardwaj, M.D., Ph.D., Mount Sinai School of Medicine, USA
Luigi Buonaguro, M.D., National Cancer Institute, Italy
Vincenzo Cerundolo, M.D., Ph.D., University of Oxford, United Kingdom
Hearn Cho, M.D., Ph.D., Mount Sinai School of Medicine, USA
George Coukos, M.D., Ph.D., University
Hospital of Lausanne (CHUV), Switzerland
Lawrence Fong, M.D., University of
California, San Francisco, USA
Sacha Gnjatic, Ph.D., Mount Sinai School
of Medicine, USA
Philip Greenberg, M.D., Fred Hutchinson
Cancer Research Center, University of
Washington, USA
F. Stephen Hodi Jr., M.D., Dana-Farber
Cancer Institute, Harvard Medical School, USA
Dirk Jäger, M.D., National Center for Tumor
Diseases, University Clinic of Heidelberg, Germany
Elke Jäger, M.D., Krankenhaus Nordwest, Germany
Elizabeth Jaffee, M.D., The Johns Hopkins
University School of Medicine, USA
Achim Jungbluth, M.D., Memorial
Sloan-Kettering Cancer Center, USA
Shinichi Kageyama, M.D., Mie University
School of Medicine, Japan
John Kirkwood, M.D., University of
Pittsburgh Medical Center, USA
Judith Kroep, M.D., Ph.D., Leiden University
Medical Center, The Netherlands
Alexander Lesokhin, M.D., Memorial
Sloan-Kettering Cancer Center, USA
Cornelis (Kees) Melief, M.D., Ph.D., Leiden University Medical Center, The Netherlands
Eiichi Nakayama, M.D., Ph.D., Kawasaki
University of Medical Welfare, Japan
Hiroyoshi Nishikawa, M.D., Ph.D., Osaka
University, Japan
Drew Pardoll, M.D., Ph.D., The Johns Hopkins University School of Medicine, USA
Marshal Posner, M.D., Mount Sinai School
of Medicine, USA
Antoni Ribas, M.D., Ph.D., UCLA, David
Geffen School of Medicine, USA
Pedro Romero, M.D., Université de
Lausanne, Switzerland
Padmanee Sharma, M.D., Ph.D., The
University of Texas MD Anderson Cancer
Center, USA
Hiroshi Shiku, M.D., Mie University School
of Medicine, Japan
Mark J. Smyth, Ph.D., Queensland Institute
of Medical Research, Australia
Daniel Speiser, M.D., Université de
Lausanne, Switzerland
Mario Sznol, M.D., Yale University, USA
Suzanne Topalian, M.D., The Johns Hopkins
University School of Medicine, USA
Danila Valmori, Ph.D., Centre de Lutte
Contre le Cancer Nantes-Atlantique, France
Maries van den Broek, Ph.D., University
of Zürich, Switzerland
Sjoerd Henricus van der Burg, Ph.D., Leiden
University Medical Center, The Netherlands
Hisashi Wada, M.D., Ph.D., Osaka University,
Japan
Ralph R. Weichselbaum, M.D., University
of Chicago, USA
Cassian Yee, M.D., The University of Texas
MD Anderson Cancer Center, USA
Hassane Zarour, M.D., University of
Pittsburgh Medical Center, USA
CANCER IMMUNOTHERAPY CONSORTIUM
Consortium Co-Directors &
Executive Committee Co-Chairs
James P. Allison, Ph.D.
The University of Texas
MD Anderson Cancer Center
Houston, TX
Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA
Executive Committee Members
Neil L. Berinstein, M.D.
Ontario Institute for Cancer Research
Toronto, Canada
Mark Frohlich, M.D.
Dendreon
Seattle, WA
Hyam Levitsky, M.D., Ph.D.
Roche Glycart AG
Schlieren, Switzerland, and
The Johns Hopkins University School of
Medicine
Baltimore, MD
Jens-Peter Marschner, M.D.
Affimed Therapeutics AG
Heidelberg, Germany
Jill O’Donnell-Tormey, Ph.D.
Cancer Research Institute
New York, NY
Kunle Odunsi, M.D., Ph.D.
Roswell Park Cancer Institute
Buffalo, NY
Gerd Ritter, Ph.D.
Ludwig Cancer Research
New York, NY
Pramod K. Srivastava, M.D., Ph.D.
University of Connecticut School of Medicine
Farmington, CT
Kerry Wentworth
Agenus, Inc.
Lexington, MA
Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center
and Ludwig Cancer Research
New York, NY
CIC Members
AbbVie Biotherapeutics Inc.
Activartis Biotech GmbH
Agenus, Inc.
The Angeles Clinic and Research Institute
APEIRON Biologics AG
Armauer Hansen Research Institute
Austin Health
Baylor Institute for Immunology Research
Benaroya Research Institute
BN ImmunoTherapeutics
Cancer Trials Australia
Cardiff University School of Medicine
Center of Molecular Immunology
Centre for International Health Research
(CRESIB) Barcelona
City of Hope
Compugen Ltd.
Dana-Farber Cancer Institute
Dartmouth Medical School
DeAR Lab Avenir, INSERM U986
Deeley Research Centre/British Columbia Cancer Agency
Duke University Medical Center
Earle A. Chiles Research Institute
Fondazione IRCCS Istituto Nazionale
dei Tumori
Fred Hutchinson Cancer Research Center
The George Washington Cancer Institute
Georgia Regents University Cancer Center
Hannover Medical School
Helmholtz Zentrum Muenchen
Hoag Hospital
Immatics Biotechnologies GmbH
Immudex
ImmunID Technologies
Imperial College London
Inovio Pharmaceuticals
Institut Curie
Johannes Gutenberg-Universität Mainz
The Johns Hopkins University School of
Medicine
Kawasaki University of Medical Welfare
Krankenhaus Nordwest
Le Centre de Lutte Contre le Cancer Nantes
Atlantique René Gauducheau
Leiden University Medical Center
London School of Hygiene and Tropical Medicine
Loyola University Medical Center, Chicago
Ludwig Cancer Research
Ludwig-Maximilans Universität München
Martin Luther University Halle-Wittenberg
Massachusetts General Hospital
Max-Planck Institute für Infektionsbiologie
McMaster University
Medical & Biological Laboratories Co., Ltd.
Medical University of Lublin
Memorial Sloan-Kettering Cancer Center
Merck KGaA
Mercy Cancer Center
Mie University
Moffitt Cancer Center
National Cancer Center Hospital (Japan)
National Cancer Institute “Pascale”
National Institutes of Health
National Jewish Health
Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
New York University School of Medicine
NewVac LLC
Northern California Melanoma Center
Okayama University Medical School
OncoTherapy Science, Inc.
Ontario Institute for Cancer Research
Osaka University
Paterson Institute for Cancer Research,
University of Manchester
Queensland Institute of Medical Research
Regeneron Pharmaceuticals
Regina Elena National Cancer Institute
Reliable Cancer Therapies
The Rockefeller University
Roswell Park Cancer Institute
Shionogi & Co., Ltd.
Stanford University
Swedish Institute for Infectious Disease Control
Tbilisi State Medical University
Transgene SA
Université de Montréal
University Hospital Lausanne
University Hospital Zürich
University Medical Center
Hamburg-Eppendorf
University of Antwerp
University of Connecticut
University of Crete
University of Erlangen-Nürnberg
University of Genoa, Italy
University of Heidelberg
University of Minnesota Masonic
Cancer Center
University of Oxford
University of Pennsylvania School
of Medicine
University of Pittsburgh Cancer Institute
University of Southampton
The University of Texas MD Anderson
Cancer Center
University of Texas Southwestern
Medical Center
University of the Witwatersrand
University of Tübingen
University of Virginia Health System
University of Washington, Seattle
University of Wisconsin Carbone
Cancer Center
University of Zürich
University Sapienza Rome
Vanderbilt University Medical Center
VU University Medical Center, Cancer
Center Amsterdam
Walter Reed Army Institute of Research
Washington University School of Medicine
Weill Cornell Medical College
YOUNG PHILANTHROPISTS COUNCIL
Chair
Alexis Feldman
Feldman Realty Group
New York, NY
Vice Chair
Samantha Knapik
On Deck Capital
New York, NY
Treasurer
Eric Adams
JP Morgan
New York, NY
Secretary
Emily Slater
Cantor Fitzgerald/BGC Partners
New York, NY
Members
Erik Arnetz
The Johnson Company
New York, NY
Robin Beltrani
GlobeTax Services, Inc.
New York, NY
George Bergamo
GIA Group
New York, NY
Anne Bracegirdle
Christie’s
New York, NY
Megan K. Bannigan
Debevoise & Plimpton LLP
New York, NY
Christina Brown
HealthFirst
New York, NY
Alfonso Chang
The AC3 Group
Relativity Healthcare Partners
New York, NY
Emily Craft
The Peter and Carmen Lucia Buck
Foundation, Inc.
New York, NY
Kate Cucco
New York State Assembly
New York, NY
CANCER RESEARCH INSTITUTE | 41
OTHER SCIENTIFIC AND LAY LEADERSHIP
Alizeh Gangji
ZS Associates
New York, NY
Lisbeth Garassino
Joe’s Sister
New York, NY
Jeffrey Gardner
Metropolitan Real Estate Equity
Management, LLC
New York, NY
Alexis Hovey
Ralph Lauren Corporation
New York, NY
Marissa Kaplan
ConMed Corporation
New York, NY
Sean Kiely
New York, NY
Mark Koch
AT&T
New York, NY
Sharon Minick
SiriusXM Radio
Hoboken, NJ
Nicole Negrin
Ralph Lauren Corporation
New York, NY
Tiffany Ofiero
Conair Corporation
New York, NY
Kristen Rathfelder
Och Ziff Capital Management
New York, NY
Marissa G. Schneider
Philosophy, Coty
New York, NY
Priyanka Sewhani
NYU Stern
New York, NY
Christine Speare
Ralph Lauren Corporation
New York, NY
Josephine Vella
Gusrae Kaplan Nusbaum PLLC
New York, NY
Kendall Wrigley
Vitech Systems Group
New York, NY
CRI STAFF
CONSULTANT
Senior Staff
Jill O’Donnell-Tormey, Ph.D.
CEO and Director of Scientific Affairs
Adam Kolom
Startist Innovations LLC
Managing Director, CRI Venture Fund
Brian M. Brewer
Director of Marketing and Communications
Lynne A. Harmer
Director of Grants Administration and
Special Events
Alfred R. Massidas
CFO and Director of Human Resources
Staff
Hannah Appelbaum
Development Associate
Rupinder Kaur
Database Administrator
Erin Kim
Events Coordinator
Michelle Liew
Digital Media Manager
Emily Livingstone
Development Associate
Alexandra S. Mulvey
Associate Director of Communications
Shasell Negron
Office Manager / Workplace Giving
Campaign Manager
Kasturi “Devi” Sharma
Donations Processing Manager
Marla Sincavage
Manager, Corporate and Foundation Giving
Matthew Tontonoz
Science Writer
Denise Upton
Grants Administrator
Jasmine Wright
Assistant to the CEO
Qing Hua Zhang
Assistant Controller
GIVING TO THE CANCER RESEARCH INSTITUTE
Call 1-800-99-CANCER or go to
www.cancerresearch.org/donate
From the laboratory research milestones achieved to the breakthrough clinical developments that are saving cancer patients, 2013 was
a year of many gifts.
If you are a donor to CRI, you deserve very special thanks, from us and from the thousands of others who have been touched
by your generosity. We are deeply grateful for your participation in our work and are honored to share in the victories we have accomplished together this year. With sustained support from our loyal friends and new interest from those who are learning about CRI and our
work for the first time, CRI can continue to be a powerful catalyst for discovery and transformation in cancer treatment.
CRI has a long tradition of responsible stewardship of donor funds. We receive the highest marks from charity watchdog groups for our
fiscal management, operational transparency, and use of donor contributions. These include an “A” grade from the American Institute
of Philanthropy, a four-star rating from the Charity Navigator, and the Wise Giving Alliance Seal of the Better Business Bureau. Donors to
CRI can be confident that their donation, in any amount, in any of the ways outlined here, will do the most good possible.
OUTRIGHT GIFTS
Cash: Donations by check or credit card to
the Cancer Research Institute may be sent
directly to the Institute or processed through
a secure page on our website at
www.cancerresearch.org/donate.
Property other than cash: Donating securities, automobiles, and similar properties can
often be a tax-efficient method for making a
meaningful gift to CRI.
Workplace giving programs: CRI is a member
of the Community Health Charities of America and its state affiliates across the country;
participates in the Combined Federal Campaign (national member #11999) as well
as corporate, state, and local and municipal
campaigns; and receives United Way Donors
Choice funds. These payroll deduction programs raise more than a million dollars each
year for CRI and are a vital source of funding
for our research programs. Your company
may have a plan through which you can
contribute to CRI. Ask your human resources
department, or call Alfred Massidas at
212-688-7515.
Matching gift programs: Many companies
double or triple charitable donations made
by their employees. Contact your human
resources department to inquire if your
employer matches contributions. You may
also browse our online matching gift program
database to see if your company is listed:
www.cancerresearch.org/give/match.
PLANNED GIFTS
The Helen Coley Nauts Society, named
after the Institute’s founder, acknowledges
those who include CRI in their financial and
estate plans. Planned gifts include bequests
made through a living trust or inclusion
of the Cancer Research Institute in your
will as a beneficiary of cash, securities,
or personal property. Bequests can take a
variety of forms, including specific dollar
amount bequests, residuary bequests, and
contingent bequests. Your bequest should
include the Institute’s federal tax ID number
(13-1837442) and a statement such as the
following:
“I bequeath to the Cancer Research Institute,
Inc., a not-for-profit corporation of the State
of New York, having its principal office at One
Exchange Plaza, 55 Broadway, Suite 1802,
New York, New York 10006, the sum of
$_____ for its general corporate purposes.”
The Helen Coley Nauts Society also includes
those who name the Institute as a beneficiary
of their life-insurance policy, retirement plan,
or lead trust; who make a life income gift
through a charitable gift annuity or charitable
remainder trust; or who establish an endowment. Many of these planned gifts can offer
donors tax advantages and income benefits
while providing support for the Institute today
or in the future. You should, of course, always
consult your attorney and tax advisor for the
formal writing of your will and to discuss
the tax implications of any form of planned
giving.
SPECIAL-PURPOSE GIVING
Memorials and special occasions: You can
make an outright or planned gift in memory
of a relative, friend, or colleague. The Institute will send an announcement of the gift to
whomever you specify. This type of donation
can also serve as a tribute in recognition
of a birthday, anniversary, holiday, or other
milestone.
Designated support: Gifts can be designated
for any of the Institute’s programs or for
geographically specific research funds. You
may prefer to designate a specific fellow or
investigator to receive your support. Benefactors receive yearly research progress reports
and are acknowledged in published papers
about the work they have supported.
Your gift is deductible for federal and state
tax purposes as provided by law; CRI is a
Section 501(c)3 nonprofit, tax-exempt organization under Section 501(a) of the Internal
Revenue Code.
To help you, your company, or your client
make the most fitting and fulfilling contribution to the Cancer Research Institute,
please contact our Development Office at
1-800-99-CANCER or send an e-mail to
[email protected].
JOIN OUR ONLINE COMMUNITY OF
FRIENDS
It’s easy to stay up-to-date on the many advances coming from CRI-supported laboratories and clinics.
Cancer ImmuNews—our e-newsletter featuring interviews with CRI scientists, stories on
advances in tumor immunology, supporter
tips, and more.
www.cancerresearch.org/e-news
Our Blog—we’ve put in one place online all
the news and updates from CRI that you
need. Read stories of discovery and survival
and give your feedback. We’d love to hear
from you. www.cancerresearch.org/blog
Facebook—more than 25,000 friends and
growing, this is a thriving group with lively
discussions about breaking cancer research
news and CRI developments.
www.facebook.com/cancerresearchinstituteinc
Twitter—join the conversation and follow
along with our live tweets from scientific
conferences. www.twitter.com/cancerresearch
CANCER RESEARCH INSTITUTE | 45
NATIONAL HEADQUARTERS
One Exchange Plaza
55 Broadway, Suite 1802
New York, NY 10006
Tel. 212-688-7515
Toll-Free 800-99-CANCER
Fax 212-832-9376
Email [email protected]
VOLUNTEER OFFICES
12011 San Vicente Boulevard
Los Angeles, CA 90049
Tel. 310-471-2720
101 University Avenue, 4th Floor
Palo Alto, CA 94301
Tel. 650-365-6441
80 Field Point Road
Greenwich, CT 06830
Tel. 203-622-0522
184 Fisher Avenue
Brookline, MA 02445
Tel. 617-566-0100
6000 Uptown Boulevard, Suite 309
Albuquerque, NM 87110
Tel. 505-234-6255
2802 Flintrock Trace, Suite 220
Austin, TX 78738
Tel. 512-610-5530
122 River Run Road
Lancaster, VA 22503
Tel. 703-759-0835
www.cancerresearch.org